Sentence,class,file
"http://dx.doi.org/   10.1083/jcb.20090411 8 Hayashi, Y ., T.R.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1242/dev.07805 5 Horne-Badovinac, S., and D. Bilder.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/   10.1002/dvdy.2028 6 Jakubovic, B.D., and S. Jothy.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1016/   j.yexmp.2006.10.01 0 Kessenbrock, K., G.J.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1016/j.stem.2013.06.00 5 Kim, M.S., A.M. Saunders, B.Y .",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1016/j.devcel.2004.08.00 4 Kreuger, J., L. Perez, A.J.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1016/j.devcel.2004.08.00 5 Lander, A.D., J. Kimble, H. Clevers, E. Fuchs, D. Montarras, M. Buckingham,  A.L.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"10:19. http://dx.doi.org/   10.1186/1741-7007-10-1 9 Li, L., and T. Xie.",Non-OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1146/annurev.cellbio.21   .012704.13152 5 Li, Q., P.W.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/   10.1016/S0092-8674(02)01079- 6 Llano, E., G. Adam, A.M. Pendás, V .",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1074/jbc.M20012120 0 Manseau, L., A. Baradaran, D. Brower, A. Budhu, F. Elefant, H. Phan, A.V .",Non-OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1002/(SICI)1097-   0177(199707)209:3<310::AID-AJA6>3.0.CO;2- L Margolis, J., and A. Spradling.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1242/dev.0219 7 Niehrs, C. 2012.",Non-OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1038/nrm347 0 Nystul, T., and A. Spradling.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1016/j.stem.2007.07.00 9 Nystul, T., and A. Spradling.",OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"184:503– 515. http://dx.doi.org/10.1534/genetics.109.10953 8 Olson, E.R., R. Pancratov, S.S. Chatterjee, B. Changkakoty, Z. Pervaiz, and R.  DasGupta.",Non-OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
"http://dx.doi.org/10.1038/embor.2011.15 9 Page-McCaw, A., J. Serano, J.M.",Non-OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
http://dx.doi.org/10.1016/S1534-   5807(02)00400- 8,OADS,/arxiv_data1/oa_pdf/9e/9a/JCB_201403084.PMC4178971.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub - lication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
Online supplemental material is available at http://www.jcb.org/cgi/con - tent/full/jcb.201405058/DC1.,Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
Additional data are available in the JCB  DataViewer at http://dx.doi.org/10.1083/jcb.201405058.dv.,OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
http://dx.doi.org/10.1016/   j.biochi.2005.10.01 1into pPacPl (FBmc0001179; FlyBase) at the SpeI sites.,OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/0092-   8674(84)90266- 6 Kim-Ha, J., K. Kerr, and P.M. Macdonald.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/0092-8674(95)90393- 3 Ladd, A.N., N. Charlet, and T.A.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi   .org/10.1128/MCB.21.4.1285-1296.200 1 Ladd, A.N., G. Taffet, C. Hartley, D.L.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10   .1128/MCB.25.14.6267-6278.200 5 Machuca-Tzili, L.E., S. Buxton, A. Thorpe, C.M.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1242/dmm.00415 0 Majczenko, K., A.E.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi   .org/10.1016/j.ajhg.2012.06.01 2 Maves, L., A.J.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1126/science.108903 5 Moore, J., H. Han, and P. Lasko.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/j.mod.2009.04.00 2 Morriss, G.R., A.L.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi   .org/10.1007/978-1-61779-343-1_ 8 Nose, A., T. Isshiki, and M. Takeichi.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1101/   gad.3.8.123 3 O’Keefe, R.T., A. Mayeda, C.L.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10   .1083/jcb.124.3.24 9 Payne, C.M., L.Z.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"25:99– 108. http://dx.doi.org/10.1016/0022-510X(75)90190- 2 Philips, A.V ., L.T.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1126/science.280.5364.73 7 Punkt, K. 2002.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"102:189– 198. http://dx.doi.org/10.1016/S0092-8674(00)00024- 6 Salz, H.K.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi   .org/10.1016/j.gde.2011.03.00 1 Savkur, R.S., A.V .",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1038/ng70 4 Schiaffino, S., and C. Reggiani.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1152/physrev.00031.201 0 Schiaffino, S., V .",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/S0074-7696(08)61874- 4 Bischof, J., R.K. Maeda, M. Hediger, F. Karch, and K. Basler.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1146/annurev   .biochem.72.121801.16172 0 Blanchette, M., R.E.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1101/gad.131420 5 Blanchette, M., R.E.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/j.molcel.2009.01.02 2 Bryantsev, A.L., P.W.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi   .org/10.1016/j.ydbio.2011.09.03 1 Bryantsev, A.L., S. Duong, T.M.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/j.devcel.2012.08.00 4 Charlet-B, N., R.S.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/S1097-2765(02)00572- 5 Dhaenens, C.M., H. Tran, M.L.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1007/BF0027358 9 Farkas-Bargeton, E., J.P. Barbet, S. Dancea, R. Wehrle, A. Checouri, and O.  Dulac.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"83:145– 159. http://dx.doi.org/10.1016/0022-510X(88)90064- 0 Filardo, P., and A. Ephrussi.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/S0925-   4773(02)00454- 9 Förch, P., and J. Valcárcel.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10   .1007/978-3-662-09728-1_ 5 Fyrberg, E.A., J.W.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/0092-8674(83)90340- 9 Gauthier, G.F. 1979.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1083/   jcb.82.2.39 1 Heidt, A.B., A. Rojas, I.S.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1128/MCB.01700-0 6 Herranz, R., C. Díaz-Castillo, T.P.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1038/sj.emboj.760030 0 Jaramillo, M.S., C.V .",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1242/dev.03156 7 Kalsotra, A., X. Xiao, A.J.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/   10.1038/nature1055 9 Silver, M.M., G.A.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10   .1016/S0046-8177(84)80312- 3 Snee, M., D. Benz, J. Jen, and P.M. Macdonald.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1016/j.yexcr   .2013.10.00 7 Swank, D.M., L. Wells, W.A.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1002/1097-0029(20000915)   50:6<430::AID-JEMT2>3.0.CO;2- E Timchenko, N.A., R. Patel, P. Iakova, Z.J.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1093/   nar/gkr64 8 Vicente, M., L. Monferrer, M.G.",Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
http://dx.doi.org/10.1111/j.1432-0436.2006.00156.,Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1371/journal.pone.000161 3 Webster, P.J., L. Liang, C.A.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"http://dx.doi.org/10.1101/   gad.11.19.251 0 Wells, L., K.A.",OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
http://dx.doi.org/10   .1371/journal.pbio.002034 8,Non-OADS,/arxiv_data1/oa_pdf/9c/a6/JCB_201405058.PMC4178973.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):359-363 http://dx.doi.org/10.3341/kjo.2014.28.5.359 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.359 Original ArticlePurpose : To determine effectiveness of laser-assisted in situ  keratomileusis (LASIK) in the treatment of astig - matism following penetrating keratoplasty (PK).",Non-OADS,/arxiv_data1/oa_pdf/5f/22/kjo-28-359.PMC4179111.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):364-372 http://dx.doi.org/10.3341/kjo.2014.28.5.364 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.364 Original ArticleMacular Hole Formation in Rhegmatogenous Retinal Detachment  after Scleral Buckling Ik Soo Byon1,2, Han Jo Kwon3, Gun Hyung Park3, Sung Who Park3, Ji Eun Lee3,4 1Department of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan, Korea 2Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea 3Department of Ophthalmology, Pusan National University Hospital, Busan, Korea 4Medical institute, Pusan National University School of Medicine, Busan, Korea Purpose : To describe early macular hole (MH) development in rhegmatogenous retinal detachment (RRD)  after  scleral buckling (SB) based on optical coherence tomography (OCT) findings.",Non-OADS,/arxiv_data1/oa_pdf/4d/e5/kjo-28-364.PMC4179112.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):373-378 http://dx.doi.org/10.3341/kjo.2014.28.5.373 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.373 Original ArticleDiabetic Retinopathy Risk Factors: Plasma Erythropoietin as a Risk  Factor for Proliferative Diabetic Retinopathy Yaghoobi Gholamhossein1,2, Heydari Behrouz1, Zarban Asghar1 1Department of Ophthalmology, Birjand University of Medical Science, Birjand, Iran 2Social Detrimental Health Research Center, Birjand, Iran Purpose:  The purpose of this st udy was to evaluate whether any stage of diabetic retinopathy (DR) is  associated with levels of plasma erythropoietin and other plasma parameters.",Non-OADS,/arxiv_data1/oa_pdf/f0/23/kjo-28-373.PMC4179113.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):379-385 http://dx.doi.org/10.3341/kjo.2014.28.5.379 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.379 Original ArticleThe Short-term Efficacy of Subthreshold Micropulse Yellow (577-nm)  Laser Photocoagulation for Diabetic Macular Edema Yoon Hyung Kwon1,2, Dong Kyu Lee2, Oh Woong Kwon2 1Department of Ophthalmology, Dong-A University College of Medicine, Busan, Korea 2Retina Center, Nune Eye Hospital, Seoul, Korea Purpose : This pilot study aimed to evaluate the efficacy and safety of subthreshold micropulse yellow (577 -nm)  laser photocoagulation (SMYLP) in the treatment of diabetic macular edema (DME).",Non-OADS,/arxiv_data1/oa_pdf/ed/d4/kjo-28-379.PMC4179114.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):386-392 http://dx.doi.org/10.3341/kjo.2014.28.5.386 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.386 Original ArticlePredictive Findings of Visual Outcome in Spectral Domain Optical  Coherence Tomography after Ranibizumab Treatment in Age-related  Macular Degeneration Yoon Hyung Kwon1,2, Dong Kyu Lee2, Hyung Eun Kim2, Oh Woong Kwon2 1Department of Ophthalmology, Dong-A University College of Medicine, Busan, Korea 2Retina Center, Nune Eye Hospital, Seoul, Korea Purpose:  To investigate which spectral domain optical coherence tomography (SD-OCT) findings predict visual  outcome after anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular  degeneration (NV-AMD).",Non-OADS,/arxiv_data1/oa_pdf/b1/97/kjo-28-386.PMC4179115.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):393-398 http://dx.doi.org/10.3341/kjo.2014.28.5.393 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.393 Original ArticleAugmentation of Filtering Blebs with Viscoelastics in Trabeculectomy Hyerin Jeong,  Kyung Rim Sung Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose:  To evaluate the clinical outcome of viscoelastics (VE, sodium hyaluronate)-augmented trabeculecto - my (VAT, 66 eyes) and conventional trabeculectomy (CT, 57 eyes) for glaucomatous eyes.",Non-OADS,/arxiv_data1/oa_pdf/54/08/kjo-28-393.PMC4179116.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):399-407 http://dx.doi.org/10.3341/kjo.2014.28.5.399 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.399 Original ArticleComparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%),  Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary  Open Angle Glaucoma Deepak Mishra1, Bibhuti Prassan Sinha1, Mahendra Singh Kumar2 1Regional Institute of Ophthalmology, Indira Gandhi Institute of Medical Sciences, Patna, India 2Department of Ophthalmology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India Purpose:  To compare the efficacy and safety of latanoprost, bimatoprost, travoprost and timolol in reducing in - traocular pressure (IOP) in patients with primary open angle glaucoma.",Non-OADS,/arxiv_data1/oa_pdf/72/14/kjo-28-399.PMC4179117.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):408-416 http://dx.doi.org/10.3341/kjo.2014.28.5.408 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.408 Original ArticleThe Effect of Pattern Scan Laser Photocoagulation on Peripapillary  Retinal Nerve Fiber Layer Thickness and Optic Nerve Morphology in  Diabetic Retinopathy Dong Eik Lee1, Ju Hyang Lee2, Han Woong Lim1, Min Ho Kang1, Hee Yoon Cho1, Mincheol Seong1 1Department of Ophthalmology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea 2Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Purpose : To evaluate  the effect of pattern scan laser (PASCAL) photocoagulation on peripapillary retinal nerve  fiber layer (RNFL) thickness , central macular thickness (CMT), and optic nerve morphology in patients with  diabetic retinopathy.",Non-OADS,/arxiv_data1/oa_pdf/e7/1c/kjo-28-408.PMC4179118.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2014;28(5):417-422 http://dx.doi.org/10.3341/kjo.2014.28.5.417 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.417 Original ArticleAccommodative Esotropia Who Needs Spectacles for Good Ocular  Alignment after Refractive Shift below +2.00 Diopters Won Jae Kim, Myung Mi Kim Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea Purpose:  The aim of this study is to investigate the clinical characteristics of patients diagnosed with refractive  accommodative esotropia (RAE) whose refractive errors were gradually reduced to below +2.00 diopters (D)  during follow-up but use of spectacles was still required for maintenance of good ocular alignment.",Non-OADS,/arxiv_data1/oa_pdf/9d/a7/kjo-28-417.PMC4179119.pdf
"pISSN: 1011-8942  eISSN: 2092-9382 © 2014 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.423Long-standing Asymptomatic In - tralenticular Foreign Body Dear Editor, Intralenticular foreign bodies are uncommon after pene - trating eye injuries, occurring in approximately 5% to 10%  of cases [1].",Non-OADS,/arxiv_data1/oa_pdf/3c/18/kjo-28-423.PMC4179120.pdf
We believe that the reasons stated  above explain why the patient did not experience any visu -Korean J Ophthalmol 2014;28(5):423-424 http://dx.doi.org/10.3341/kjo.2014.28.5.423 Fig.,Non-OADS,/arxiv_data1/oa_pdf/3c/18/kjo-28-423.PMC4179120.pdf
1I Korean J Ophthalmol 2014;28(5):424-426 http://dx.doi.org/10.3341/kjo.2014.28.5.424,Non-OADS,/arxiv_data1/oa_pdf/3c/18/kjo-28-423.PMC4179120.pdf
1I Korean J Ophthalmol 2014;28(5):424-426 http://dx.doi.org/10.3341/kjo.2014.28.5.424,Non-OADS,/arxiv_data1/oa_pdf/be/52/kjo-28-424.PMC4179121.pdf
Korean J Ophthalmol 2014;28(5):426-428 http://dx.doi.org/10.3341/kjo.2014.28.5.426,Non-OADS,/arxiv_data1/oa_pdf/be/52/kjo-28-424.PMC4179121.pdf
Korean J Ophthalmol 2014;28(5):426-428 http://dx.doi.org/10.3341/kjo.2014.28.5.426,Non-OADS,/arxiv_data1/oa_pdf/ab/ab/kjo-28-426.PMC4179122.pdf
A Korean J Ophthalmol 2014;28(5):428-429 http://dx.doi.org/10.3341/kjo.2014.28.5.428,Non-OADS,/arxiv_data1/oa_pdf/ab/ab/kjo-28-426.PMC4179122.pdf
A Korean J Ophthalmol 2014;28(5):428-429 http://dx.doi.org/10.3341/kjo.2014.28.5.428,Non-OADS,/arxiv_data1/oa_pdf/fc/88/kjo-28-428.PMC4179123.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/18/37/srep06408.PMC4179124.pdf
"NGDC NOAA, The yearly sunspot number dataset, ftp://ftp.ngdc.noaa.gov/STP/ space-weather/solar-data/solar-indices/sunspot-numbers/international/listings/listing_international-sunspot-numbers_yearly.txt.",OADS,/arxiv_data1/oa_pdf/85/bc/srep06502.PMC4179127.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/85/bc/srep06502.PMC4179127.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/6c/5b/srep06505.PMC4179128.pdf
Cells 2014; 37(9): 637-643  http://dx.doi.org/10.14348/molcells.2014.0150        eISSN: 0219-1032   The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
Proline residues   Molecules and Cells http://molcells.org   Established in 1990,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
Cells http://molcells.org                                           Fig.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
Cells http://molcells.org                                                   signaling in hyperglycemic diabetic wounds.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
Cells http://molcells.org     6195.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/0d/55/molcell-37-9-637.PMC4179131.pdf
Cells 2014; 37(9): 644-649  http://dx.doi.org/10.14348/molcells.2014.0177        eISSN: 0219-1032   The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
"These in cluded near- ly all previously identified 3  processing factors, with the exception  Molecules and Cells http://molcells.org     Established in 1990",OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
Connecting Polyadenylation to Diverse Nuclear Pathways  Dafne Campigli Di Giammartino & James L. Manley      http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
"Cells http://molcells.org                                           Glc7 functions in mRNA expor t, through dephosphorylation of  Npl3 (Gilbert and Guthrie, 2004).",Non-OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
Connecting Polyadenylation to Diverse Nuclear Pathways  Dafne Campigli Di Giammartino & James L. Manley      http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
"Cells http://molcells.org     could be by using one of the several small molecule inhibitors of  DNA-PK (Davidson et al., 2013),  and determine whether it af- fects 3 cleavage activity, either in the presence or absence of  DNA damage.",Non-OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
Connecting Polyadenylation to Diverse Nuclear Pathways  Dafne Campigli Di Giammartino & James L. Manley      http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/54/b3/molcell-37-9-644.PMC4179132.pdf
Cells 2014; 37(9): 650-655  http://dx.doi.org/10.14348/molcells.2014.0010       eISSN: 0219-1032   The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
The  Molecules and Cells http://molcells.org   Established in 1990,Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
Cells http://molcells.org      A                     B                     C                   A                     B                     C               D                     E                     F               BM-MSCs after exposure to neurogenic medium.,Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
Cells http://molcells.org     that labeled cells could be tracked with MRI in vitro  for extended  periods of time following labeling.,Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/0d/ba/molcell-37-9-650.PMC4179133.pdf
Cells 2014; 37(9): 656-663  http://dx.doi.org/10.14348/molcells.2014.0087      eISSN: 0219-1032   The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
Recent reports have shown that ginseng also contains a ligand for the G protein-coupled  lysophosphatidic acid (LPA) receptor called gintonin (Hwang et  Molecules and Cells http://molcells.org   Established in 1990,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
"Cells http://molcells.org                         A                            B                        C                               D                      histogram shows blockage of gintonin-mediated IKs channel activation by the LPA1/3 receptor antagonist, Ki16425.",Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
Cells http://molcells.org      A                          B                            Fig.,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
Cells http://molcells.org                                        change Ca 2+/CaM binding in a differential manner.,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/e9/55/molcell-37-9-656.PMC4179134.pdf
Cells 2014; 37(9): 664-671  http://dx.doi.org/10.14348/molcells.2014.0121    664  Mol.,OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
Cells http://molcells.org         eISSN: 0219-1032  The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
"To  view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
"However, the association of other  miRNA expression with the sensitivity of lung cancer cells to  Molecules and Cells http://molcells.org   Established in 1990",Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
Cells http://molcells.org      A                                                        B                             Fig.,Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
Cells http://molcells.org      A                                           B                              and untreated groups at 24 and 36 h after wound creation (Fig.,Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
"Cells http://molcells.org        A                           B                    C                          D                   E                           F                      G                                 H                            says on cell proliferation, apoptosis, migration and invasion may  be used to further understand the mechanism by which miR-217 contributes to lung cancer tumourigenesis and progression.",Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/90/3b/molcell-37-9-664.PMC4179135.pdf
Cells 2014; 37(9): 672-684  http://dx.doi.org/10.14348/molcells.2014.0173   672  Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Cells http://molcells.org       eISSN: 0219-1032  The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
"To  view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
"Information for each  pathway can be obtained from pathway databases such as  KEGG (Kanehisa et al., 2012) and Reactome (Croft et al., 2014),  which describe metabolic pathways and gene signaling net- works and offer the potential for more complex and useful analy- Molecules and Cells http://molcells.org   Established in 1990",OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Perturbed Pathways in PD from Gene Expression Data  Jin Hwan Do      http://molcells.org Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
"In this study, I identified pathways that were sig-nificantly perturbed after treatment with MPP + using the list of  DEGs and their expression values with the commercial software  Pathway Guide 3.0 (http://www.advaitabio.com).",OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Identification of pathways that are perturbed by MPP +  treatment Significantly perturbed pathways in MPP + treated human  neuroblastoma SH-EP cells were identified using the commer- cial software Pathway Guide 3.0 (http://www.advaitabio.com/).,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Cells http://molcells.org     Table 1.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Perturbed Pathways in PD from Gene Expression Data  Jin Hwan Do     http://molcells.org Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Cells http://molcells.org     Table 2.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Perturbed Pathways in PD from Gene Expression Data  Jin Hwan Do     http://molcells.org Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
"To examine  pathways that are significantly perturbed by MPP+ treatment, two  independent probability values, PNDE and PPERT, were calculated  for each pathway with incorporating parameters such as the  normalized fold change of the DEGs, statistical significance of  the set of pathway genes, and the topology of the signaling pathway using the commercial software Pathway Guide 3.0  (http://www.advaitabio.com; see “Materials and Methods” for  details).",OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Cells http://molcells.org     Table 3.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Perturbed Pathways in PD from Gene Expression Data  Jin Hwan Do     http://molcells.org Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Cells http://molcells.org                                                                                                            Fig.,Non-OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Perturbed Pathways in PD from Gene Expression Data  Jin Hwan Do     http://molcells.org Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
"Cells http://molcells.org     type I ( IL1R1 ) induced upregulation of caspase 3 ( CASP3 ),  whereas perturbation of FAS and TGFB1 resulted in upregulation  of death-domain associated protein ( DAXX ) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Perturbed Pathways in PD from Gene Expression Data  Jin Hwan Do     http://molcells.org Mol.,OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
"Cells http://molcells.org     Asari, S., and Ohmoto, T. (1993).",OADS,/arxiv_data1/oa_pdf/0b/43/molcell-37-9-672.PMC4179136.pdf
Cells 2014; 37(9): 685-690  http://dx.doi.org/10.14348/molcells.2014.0179    685  Mol.,OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
Cells http://molcells.org       eISSN: 0219-1032  The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
"To  view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
Geno- Molecules and Cells http://molcells.org   Established in 1990,OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
Cells http://molcells.org     typing was performed according to the protocol supplied by The  Jackson Laboratory.,OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
Cells http://molcells.org      A                                              B                 C                Fig.,Non-OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
"Cells http://molcells.org     Teitelbaum, S.L.",Non-OADS,/arxiv_data1/oa_pdf/ee/35/molcell-37-9-685.PMC4179137.pdf
Cells 2014; 37(9): 691-698  http://dx.doi.org/10.14348/molcells.2014.0184    691  Mol.,OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
Cells http://molcells.org       eISSN: 0219-1032  The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
Molecules and Cells http://molcells.org   Established in 1990,OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
Cells http://molcells.org      A                               B                      Fig.,Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
Cells http://molcells.org      A                                        C                        B                                        D                                Fig.,Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
Cells http://molcells.org      A                                B                           C                          Fig.,Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
"Cells http://molcells.org     Forman, J.J., Legesse-Miller, A., and Coller, H.A.",OADS,/arxiv_data1/oa_pdf/a6/b2/molcell-37-9-691.PMC4179138.pdf
Cells 2014; 37(9): 699-704  http://dx.doi.org/10.14348/molcells.2014.0029        eISSN: 0219-1032   The Korean Society for Molecular and Cellular Biology.,OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
Molecules and Cells http://molcells.org   Established in 1990,OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
Cells http://molcells.org      A                                    B                        C                       Fig.,Non-OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
Cells http://molcells.org      A                                       B                    C                                       D                       E                   Fig.,Non-OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
http://molcells.org Mol.,Non-OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
Cells http://molcells.org     ute to aggressiveness of breast ca rcinoma.,Non-OADS,/arxiv_data1/oa_pdf/fb/b5/molcell-37-9-699.PMC4179139.pdf
"Generation of the distance matrix from any of these D2methods is implemented in a JAVA program, JIWA, which is freely available at http://bioinformatics.org.au/tools/jiwa/.",OADS,/arxiv_data1/oa_pdf/b6/f0/srep06504.PMC4179140.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b6/f0/srep06504.PMC4179140.pdf
"See http://creativecommons.org /licenses/by-nc-nd/3.0/ for details.e4 Diabetes Volume 63, April 2014eLETTERS –COMMENTS AND RESPONSES",Non-OADS,/arxiv_data1/oa_pdf/f4/aa/e4.PMC4179312.pdf
See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.,Non-OADS,/arxiv_data1/oa_pdf/f2/10/1289.PMC4179314.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"2 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"and co-selection ofmacrolide- andglycopeptide-resistant E. faecium in the animal group fed the high level of Cu.Zinc and copper in animal feed Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"4 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"It is notZinc and copper in animal feed Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"6 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"Proc Natl Acad Sci U S A 2013; 110:3435 /C144.Zinc and copper in animal feed Citation: Microbial Ecology in Health & Disease 2014, 25: 25862 - http://dx.doi.org/10.3402/mehd.v25.25862 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/3e/MEHD-25-25862.PMC4179321.pdf
"449Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fa/63/aps-41-449.PMC4179345.pdf
"452Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6e/af/aps-41-452.PMC4179346.pdf
"458Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a2/b7/aps-41-458.PMC4179347.pdf
"466Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e4/d1/aps-41-466.PMC4179348.pdf
"472Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3e/c2/aps-41-472.PMC4179349.pdf
"480Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b9/7f/aps-41-480.PMC4179350.pdf
"486Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/61/ea/aps-41-486.PMC4179351.pdf
"Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/4c/aps-41-493.PMC4179352.pdf
"500Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/03/aps-41-500.PMC4179353.pdf
Available from: http://www.cancerre - searchuk.org/cancer-info/cancerstats/incidence/all-can - cers-combined/.,Non-OADS,/arxiv_data1/oa_pdf/6c/03/aps-41-500.PMC4179353.pdf
Avail - able from: http://www.cancerresearchuk.org/cancer-info/ cancerstats/types/skin/?script=true.,Non-OADS,/arxiv_data1/oa_pdf/6c/03/aps-41-500.PMC4179353.pdf
Available from:  http://www.thh.nhs.uk/documents/_Departments/Can - cer/NHSCancerPlan.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6c/03/aps-41-500.PMC4179353.pdf
Available from: http://webarchive.nationalarchives.gov.,Non-OADS,/arxiv_data1/oa_pdf/6c/03/aps-41-500.PMC4179353.pdf
"Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/71/ed/aps-41-505.PMC4179354.pdf
"Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/94/a1/aps-41-513.PMC4179355.pdf
"520Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a4/1c/aps-41-520.PMC4179356.pdf
"Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2a/7c/aps-41-529.PMC4179357.pdf
Available from: http://www.kbcs.or.kr/.,Non-OADS,/arxiv_data1/oa_pdf/2a/7c/aps-41-529.PMC4179357.pdf
"Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/77/f3/aps-41-535.PMC4179358.pdf
http://dx.doi.org./0.1097/SAP .0b013e31828bb1e3.,OADS,/arxiv_data1/oa_pdf/77/f3/aps-41-535.PMC4179358.pdf
"542Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/0a/aps-41-542.PMC4179359.pdf
"The surgeon should have to prepare for  Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/0a/aps-41-542.PMC4179359.pdf
"550Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/df/70/aps-41-550.PMC4179360.pdf
"556Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ac/45/aps-41-556.PMC4179361.pdf
"562Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/0e/aps-41-562.PMC4179362.pdf
"Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9e/26/aps-41-571.PMC4179363.pdf
"576Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/b1/aps-41-576.PMC4179364.pdf
"584Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f4/ef/aps-41-584.PMC4179365.pdf
"588Copyright © 2014  The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/05/6e/aps-41-588.PMC4179366.pdf
"Received: 28 Sep 2013 • Revised: 10 Jun 2014 • Accepted: 10 Jun 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/10.5999/aps.2014.41.5.594 • Arch Plast Surg 2014;41:594-596 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is  properly cited.modification of the buttocks is as common as breast procedures [1].",Non-OADS,/arxiv_data1/oa_pdf/08/f9/aps-41-594.PMC4179367.pdf
"Received: 14 Mar 2014 • Revised: 17 Mar 2014 • Accepted: 17 Mar 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/10.5999/aps.2014.41.5.596 • Arch Plast Surg 2014;41:596-597 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is  properly cited.Letters",Non-OADS,/arxiv_data1/oa_pdf/08/f9/aps-41-594.PMC4179367.pdf
"Received: 14 Mar 2014 • Revised: 17 Mar 2014 • Accepted: 17 Mar 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/10.5999/aps.2014.41.5.596 • Arch Plast Surg 2014;41:596-597 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium, provided the original work is  properly cited.Letters",Non-OADS,/arxiv_data1/oa_pdf/0b/3c/aps-41-596.PMC4179368.pdf
"Received: 10 Apr 2014 • Revised: 4 May 2014 • Accepted: 14 May 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.598 • Arch Plast Surg 2014;41:598-600 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/e2/aps-41-598.PMC4179369.pdf
"Received: 17 Feb 2014 • Revised: 18 Apr 2014 • Accepted: 18 Apr 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.600 • Arch Plast Surg 2014;41:600-602 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Images",Non-OADS,/arxiv_data1/oa_pdf/84/e2/aps-41-598.PMC4179369.pdf
"Received: 17 Feb 2014 • Revised: 18 Apr 2014 • Accepted: 18 Apr 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.600 • Arch Plast Surg 2014;41:600-602 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Images",Non-OADS,/arxiv_data1/oa_pdf/8a/52/aps-41-600.PMC4179370.pdf
"Received: 15 Mar 2014 • Revised: 15 Apr 2014 • Accepted: 15 Apr 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.603 • Arch Plast Surg 2014;41:603-604 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4c/11/aps-41-603.PMC4179371.pdf
"Received: 19 Jun 2014 • Revised: 25 Jun 2014 • Accepted: 25 Jun 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.605 • Arch Plast Surg 2014;41:605-606 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.characteristics and boundaries of the mass.",Non-OADS,/arxiv_data1/oa_pdf/44/c1/aps-41-605.PMC4179372.pdf
"Received: 20 May 2014 • Revised: 17 Jun 2014 • Accepted: 1 Jul 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.607 • Arch Plast Surg 2014;41:607-609 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/da/aps-41-607.PMC4179373.pdf
"Received: 4 Mar 2014 • Revised: 8 Apr 2014 • Accepted: 24 Apr 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.609 • Arch Plast Surg 2014;41:609-612 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.of a direct incision above mass or an eyebrow incision  leave a visible scar and also caused eyebrow depilation  and hypopigmentation [2].",Non-OADS,/arxiv_data1/oa_pdf/9a/da/aps-41-607.PMC4179373.pdf
"Received: 4 Mar 2014 • Revised: 8 Apr 2014 • Accepted: 24 Apr 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.609 • Arch Plast Surg 2014;41:609-612 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.of a direct incision above mass or an eyebrow incision  leave a visible scar and also caused eyebrow depilation  and hypopigmentation [2].",Non-OADS,/arxiv_data1/oa_pdf/a7/ea/aps-41-609.PMC4179374.pdf
"Received: 23 Apr 2014 • Revised: 16 May 2014 • Accepted: 3 Jun 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.612 • Arch Plast Surg 2014;41:612-615 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a7/ea/aps-41-609.PMC4179374.pdf
"Received: 23 Apr 2014 • Revised: 16 May 2014 • Accepted: 3 Jun 2014   pISSN: 2234-6163 • eISSN: 2234-6171   http://dx.doi.org/ 10.5999/aps.2014.41.5.612 • Arch Plast Surg 2014;41:612-615 Copyright  2014 The Korean Society of Plastic and Reconstructive Surgeons This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/e2/aps-41-612.PMC4179375.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/39/fc/ceg-7-345.PMC4179399.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical and Experimental Gastroenterology 2014:7 345–358Clinical and Experimental Gastroenterology Dove press submit your manuscript | www.dovepress.co m Dove press  345REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEG.S5209 7Clinical potential of naloxegol in the management  of opioid-induced bowel dysfunction Jakob Lykke Poulsen1 Christina Brock1,2 Anne Estrup Olesen1,2 Matias Nilsson1 Asbjørn Mohr Drewes1,3 1Mech-Sense, Department   of Gastroenterology and   Hepatology, Aalborg University   Hospital, Aalborg, Denmark;   2Department of Drug Design   and Pharmacology, University   of Copenhagen, Copenhagen,   Denmark;  3Department of   Clinical Medicine, Aalborg   University, Aalborg, Denmark Correspondence: Asbjørn Mohr Drewes   Mech-Sense, Department of   Gastroenterology and Hepatology, Aalborg   University Hospital, Mølleparkvej  4,   DK-9000 Aalborg, Denmark   Tel +45 9766 3562  Fax +45 9766 3577  Email amd@rn.d kAbstract:  Opioid-induced bowel dysfunction (OIBD) is a burdensome condition which  limits the therapeutic benefit of analgesia.",Non-OADS,/arxiv_data1/oa_pdf/39/fc/ceg-7-345.PMC4179399.pdf
"Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-and-experimental-gastroenterology-journa lClinical and Experimental Gastroenterology is an international, peer- reviewed, open access journal, publishing all aspects of gastroenterology  in the clinic and laboratory, including: Pathology, pathophysiology  of gastrointestinal disease; Investigation and treatment of gastointes - tinal disease; Pharmacology of drugs used in the alimentary tract; Immunology/genetics/genomics related to gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/39/fc/ceg-7-345.PMC4179399.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/39/fc/ceg-7-345.PMC4179399.pdf
Available from http://www.nektar.com/pdf/ pipeline/NKTR-118/NKTR-118_Phase_1_APS_Poster_20080507.,Non-OADS,/arxiv_data1/oa_pdf/39/fc/ceg-7-345.PMC4179399.pdf
"Available at: http://www.fda.gov/ downloads/  AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anesthetic  AndAnalgesicDrugProductsAdvisoryCommittee/ UCM400209.pd f. Accessed August 14, 2014.",Non-OADS,/arxiv_data1/oa_pdf/39/fc/ceg-7-345.PMC4179399.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fd/39/dmso-7-437.PMC4179401.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 437–444Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  437Original reSearchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/DMSO.S6784 5The effect of a lifestyle intervention   on me tabolic health in young women Sarah l Dunn1 Winnie Siu2 Judith Freund2,3 Stephen h Boutcher2 1Department of Kinesiology,   University of la Verne, ca, USa;   2School of Medical Sciences, Faculty  of Medicine, University of new South  Wales, n SW, australia; 3St Vincent’s  hospital, nSW, australia correspondence: Sarah l Dunn   Department of Kinesiology, University   of la Verne, 1950 Third St, la Verne,   ca 91750, USa   Tel +1 909 448 4756   Fax +1 909 392 2760   email sdunn@laverne.ed uAbstract:  With the increasing obesity rates in Western countries, an effective lifestyle inter - vention for fat reduction and me tabolic benefits is needed.",Non-OADS,/arxiv_data1/oa_pdf/fd/39/dmso-7-437.PMC4179401.pdf
"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journa lDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy is  an international, peer-reviewed open-access journal committed to  the rapid publication of the latest laboratory and clinical findings  in the fields of diabetes, metabolic syndrome and obesity research.",Non-OADS,/arxiv_data1/oa_pdf/fd/39/dmso-7-437.PMC4179401.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/fd/39/dmso-7-437.PMC4179401.pdf
"Available from: http://www.idf.org/ webdata/ docs/MetS_def_update2006.pd f. Accessed August 7, 2014.",Non-OADS,/arxiv_data1/oa_pdf/fd/39/dmso-7-437.PMC4179401.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005253).,Non-OADS,/arxiv_data1/oa_pdf/ff/fa/bmjopen-2014-005253.PMC4179405.pdf
"For the purposes of this paper, the core report plus all its appendices will be known as the full clinical study report (see online supplementary appendix 1 forthe table of contents of a typical oseltamivir clinical study report and http://dx.doi.org/10.5061/dryad.77471 for a free download of all the clinical study reports used in ourreview and featured in this paper.",Non-OADS,/arxiv_data1/oa_pdf/ff/fa/bmjopen-2014-005253.PMC4179405.pdf
Data sharing statement The source core reports and clinical study reports can be found at http://datadryad.org/resource/doi:10.5061/dryad.77471.,OADS,/arxiv_data1/oa_pdf/ff/fa/bmjopen-2014-005253.PMC4179405.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.Structure and Content of Clinical Study Reports: E3 [Internet].,Non-OADS,/arxiv_data1/oa_pdf/ff/fa/bmjopen-2014-005253.PMC4179405.pdf
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/ff/fa/bmjopen-2014-005253.PMC4179405.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005647).,Non-OADS,/arxiv_data1/oa_pdf/19/fc/bmjopen-2014-005647.PMC4179407.pdf
"Quality Account 2012 –13, 2013. http://www.uhb.nhs.uk/Downloads/pdf/ QualityAccount12-13.pdf ( accessed 19 Sept 2014).",Non-OADS,/arxiv_data1/oa_pdf/19/fc/bmjopen-2014-005647.PMC4179407.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 006065).,Non-OADS,/arxiv_data1/oa_pdf/ab/2a/bmjopen-2014-006065.PMC4179409.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005575).,Non-OADS,/arxiv_data1/oa_pdf/f9/df/bmjopen-2014-005575.PMC4179411.pdf
"viewed on standard mediastinal windows, were reviewed using iSite PACS (Philips iSite Enterprise, V .3.6.114;http://www.healthcare.philips.com).",OADS,/arxiv_data1/oa_pdf/f9/df/bmjopen-2014-005575.PMC4179411.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/67/f5/bmjopen-2014-005898.PMC4179414.pdf
Presented at theCHD national transfer meeting 2004 and the British CardiacSociety annual meeting 2004. http://www.heart.nhs.uk 8.,Non-OADS,/arxiv_data1/oa_pdf/15/0c/bmjopen-2014-005525.PMC4179416.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-005532).,Non-OADS,/arxiv_data1/oa_pdf/40/e2/bmjopen-2014-005532.PMC4179420.pdf
Data sharing statement Patient level data are available from Population Data BC (https://www.popdata.bc.ca/).,OADS,/arxiv_data1/oa_pdf/40/e2/bmjopen-2014-005532.PMC4179420.pdf
http://www.nesug.org/proceedings/nesug06/an/da01.pdf (accessed 12 Nov 2010).,OADS,/arxiv_data1/oa_pdf/40/e2/bmjopen-2014-005532.PMC4179420.pdf
http://support.sas.com/resources/papers/proceedings09/237-2009.pdf (accessed 12 Nov 2010).,OADS,/arxiv_data1/oa_pdf/40/e2/bmjopen-2014-005532.PMC4179420.pdf
https://www.health.gov.bc.ca/exforms/pharmacare/5345fil.pdf (accessed 10 May 2012).,Non-OADS,/arxiv_data1/oa_pdf/40/e2/bmjopen-2014-005532.PMC4179420.pdf
http://acr.confex.com/acr/2006/webprogram/Paper5515.html (accessed 5 Dec 2011).,OADS,/arxiv_data1/oa_pdf/40/e2/bmjopen-2014-005532.PMC4179420.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-006136).,Non-OADS,/arxiv_data1/oa_pdf/00/24/bmjopen-2014-006136.PMC4179422.pdf
Data sharing statement Extra data can be accessed via the Dryad data repository at http://datadryad.org/ with the doi:10.5061/dryad.h23d1.,OADS,/arxiv_data1/oa_pdf/00/24/bmjopen-2014-006136.PMC4179422.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/00/24/bmjopen-2014-006136.PMC4179422.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005297).,Non-OADS,/arxiv_data1/oa_pdf/25/07/bmjopen-2014-005297.PMC4179424.pdf
http://www.crd.York.ac.UK/PROSPERO/display_record.asp?ID=CRD42013006702.,Non-OADS,/arxiv_data1/oa_pdf/25/07/bmjopen-2014-005297.PMC4179424.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6469 | DOI: 10.1038/srep06469 6",Non-OADS,/arxiv_data1/oa_pdf/86/46/srep06469.PMC4179463.pdf
"Table 2 |Position and distribution of Trp residues in structures of known transmembrane barrels S. No.a,bPDB IDcProteina,b#o fb-strandsd,e# of Trp residuesPosition of Trp residued Membrane interface Transmembrane Extra-membrane 1 1P4T NspA 10 (8) 0 - - - 2 2POR Porin 22 (16) 1 1 - -3 3QRA Ail 9 (8) 2 1 1 -4 1QJ8 OmpX 8 (8) 2 1 1 -5 2LHF OprH 10 (8) 2 2 - -6 3HW9 OmpF 25 (16) 2 1 1 -7 1E54 Omp32 24 (16) 2 - 1 18 3DZM TtoA 14 (8) 3 1 - 29 3FID LpxR 17 (12) 3 - 1 210 2X27 OprG 17 (8) 4 4 - -11 3BRY TbuX 27 (14) 4 2 2 -12 1K24 OpcA 15 (10) 4 3 1 -13 1UYN NalP 14 (12) 4 3 - 114 1H6S Porin 19 (16) 4 3 1 - 15 3EMO Hia [6 (4)]x3 f11 - - 16 4FQE KdgM 14 (12) 3 2 - 117 1UUN MspA [14 (2)]x8 f43 1 - 18 3WI4 PorB [22 (16)]x3f43 - 1 19 1WP1 OprM [13 (4)]x3f42 - 2 20 2LME YadA [5 (4)]x3f21 - 1 aNon-redundant structures were retrieved from PDBTM: Protein Data Bank of Transmembrane Proteins; http://pdbtm.enzim.hu/.",OADS,/arxiv_data1/oa_pdf/07/6e/srep06508.PMC4179465.pdf
cPDB: RCSB Protein Data Bank; http://www.rcsb.org/pdb.,OADS,/arxiv_data1/oa_pdf/07/6e/srep06508.PMC4179465.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/07/6e/srep06508.PMC4179465.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6508 | DOI: 10.1038/srep06508 11",Non-OADS,/arxiv_data1/oa_pdf/07/6e/srep06508.PMC4179465.pdf
Available at: http://www.idf.org/media-events/press-releases/2011/diabetes-atlas- 5th-edition (2013) (Date of access: 09/03/14).,Non-OADS,/arxiv_data1/oa_pdf/4a/a3/srep06465.PMC4179469.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/4a/a3/srep06465.PMC4179469.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/68/6d/srep06397.PMC4179471.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseApril 2014 |  86  | e50549 | Page 1 of 8Video Article Surface Passivation for Single-molecule Protein Studies Stanley D. Chandradoss1, Anna C. Haagsma1, Young Kwang Lee2, Jae-Ho Hwang2, Jwa-Min Nam2, Chirlmin Joo1 1Kavli Institute of NanoScience, Department of BioNanoScience, Delft University of Technology 2Department of Chemistry, Seoul National University Correspondence to: Chirlmin Joo at C.Joo@tudelft.nl URL: http://www.jove.com/video/50549 DOI: doi:10.3791/50549 Keywords: Chemistry, Issue 86, single-molecule spectroscopy, polymer, polyethylene glycol (PEG), piranha etching, amino-silanization, surface passivation, fluorescence, glass surface coating.",Non-OADS,/arxiv_data1/oa_pdf/0a/df/jove-86-50549.PMC4179479.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/50549/ Introduction When performing a single-molecule protein study it is essential to achieve a high quality of surface passivation so that the experiment is free from any surface-induced protein malfunction or denaturation 1,2.",Non-OADS,/arxiv_data1/oa_pdf/0a/df/jove-86-50549.PMC4179479.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseApril 2014 |  86  | e51184 | Page 1 of 10Video Article Construction and Characterization of External Cavity Diode Lasers for Atomic Physics Kyle S. Hardman1, Shayne Bennetts1, John E. Debs1, Carlos C. N. Kuhn1, Gordon D. McDonald1, Nick Robins1 1Department of Quantum Science, The Australian National University Correspondence to: Kyle S. Hardman at hardmankyle@gmail.com URL: http://www.jove.com/video/51184 DOI: doi:10.3791/51184 Keywords: Physics, Issue 86, External Cavity Diode Laser, atomic spectroscopy, laser cooling, Bose-Einstein condensation, Zeeman modulation Date Published: 4/24/2014 Citation: Hardman, K.S., Bennetts, S., Debs, J.E., Kuhn, C.C.N., McDonald, G.D., Robins, N. Construction and Characterization of External Cavity Diode Lasers for Atomic Physics.",Non-OADS,/arxiv_data1/oa_pdf/2c/16/jove-86-51184.PMC4179497.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51184/ Introduction Measuring and manipulating the quantum state of atoms is at the heart of atomic physics and requires the ability to address specific transitions between atomic electronic states.,Non-OADS,/arxiv_data1/oa_pdf/2c/16/jove-86-51184.PMC4179497.pdf
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1525/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/85/59/428.PMC4179505.pdf
"See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.Wenhui Zhao,1Peter T. Katzmarzyk,1 Ronald Horswell,1Yujie Wang,1 Jolene Johnson,2and Gang Hu1428 Diabetes Care Volume 37, February 2014EPIDEMIOLOGY/HEALTH SERVICES RESEARCH",Non-OADS,/arxiv_data1/oa_pdf/85/59/428.PMC4179505.pdf
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1904/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/04/e1/1554.PMC4179516.pdf
"See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.Fergus J. Cameron,1Shannon E. Scratch,1 Caroline Nadebaum,1 Elisabeth A. Northam,2Ildiko Koves,1 Juliet Jennings,1Kristina Finney,3 Jeffrey J. Neil,3R.",Non-OADS,/arxiv_data1/oa_pdf/04/e1/1554.PMC4179516.pdf
All participants were treatedper standard hospital protocol (http://www.rch.org.au/clinicalguide/guideline_index/Diabetes_Mellitus).,Non-OADS,/arxiv_data1/oa_pdf/04/e1/1554.PMC4179516.pdf
4 (http://surfer.nmr.mgh.harvard.edu)using the T1-weighted images.,OADS,/arxiv_data1/oa_pdf/04/e1/1554.PMC4179516.pdf
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-1745/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/18/27/1706.PMC4179517.pdf
"See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.Devjit Tripathy,1Stephen C. Clement,2 Dawn C. Schwenke,3,4MaryAnn Banerji,5 George A. Bray,6Thomas A. Buchanan,7 Amalia Gastaldelli,8Robert R. Henry,9 Abbas E. Kitabchi,10Sunder Mudaliar,9 Robert E. Ratner,11Frankie B. Stentz,10 Nicolas Musi,1Peter D. Reaven,3and Ralph A. DeFronzo11706 Diabetes Care Volume 37, June 2014PATHOPHYSIOLOGY/COMPLICATIONS",Non-OADS,/arxiv_data1/oa_pdf/18/27/1706.PMC4179517.pdf
"See http://creativecommons.org/licenses/by-nc-nd/3.0/for details.Philippe A. Halban,1 Kenneth S. Polonsky,2 Donald W. Bowden,3 Meredith A. Hawkins,4Charlotte Ling,5 Kieren J. Mather,6Alvin C. Powers,7 Christopher J. Rhodes,8Lori Sussel,9and Gordon C. Weir10Diabetes Care Volume 37, June 2014 1751CONSENSUS REPORT",Non-OADS,/arxiv_data1/oa_pdf/88/da/1751.PMC4179518.pdf
"See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.Courtney M. Peterson,1 Virgile Lecoultre,1,2 Jean-Marc Schwarz,3and Eric Ravussin1Diabetes Care Volume 37, June 2014 e157eLETTERS –COMMENTS AND RESPONSES",Non-OADS,/arxiv_data1/oa_pdf/0e/44/e157.PMC4179519.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2014-006318).,Non-OADS,/arxiv_data1/oa_pdf/80/ef/bmjopen-2014-006318.PMC4179566.pdf
Rev Esp Anestesiol Reanim 2012. http://dx.doi.org/10.1016/j.redar.2012.,OADS,/arxiv_data1/oa_pdf/80/ef/bmjopen-2014-006318.PMC4179566.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005480).,Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
Kidney Int Suppl 2013;3:1 –150.http://www.kdigo.org/ clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf(accessed 16 Mar 2014).,Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"UK Renal Registry, 2011. http://www.renalreg.com/Report-Area/Report%202011/Chap02_Renal11_web.pdf.",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"London: Department of Health, 2005. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/199002/ National_Service_Framework_for_Renal_Services_Part_Two_-_ Chronic_Kidney_Disease__Acute_Renal_Failure_and_End_of_Life_Care.pdf (accessed 16 Mar 2014).",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"London: NHS Employers and British Medical Association, 2011. http://www.nhsemployers.org/Aboutus/Publications/Documents/QOF_guidance_GMS_contract_2011_12.pdf (accessed 16 Mar 2014).",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"London: Department of Health, 2013. http://www.healthcheck.nhs.uk/commissioners_and_healthcare_professionals/national_guidance/ (accessed 16 Mar 2014).",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"London: The Stationery Office, 2004. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4098912.pdf (accessed 16 Mar2014).",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"Leeds: Health and Social Care Information Centre, 2010. http://www.hscic.gov.uk/pubs/hse09report (accessed 16 Mar 2014).",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
https://www.gov.uk/ government/uploads/system/uploads/attachment_data/file/216484/dh_128550.pdf (accessed 22 Jun 2014).,OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
"London: Department of Health, 2012. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213420/Sodium-Survey-England-2011_Text_to-DH_FINAL1.pdf (accessed 16 Mar 2014).",Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
http://www.hscic.gov.uk/ catalogue/PUB04431 (accessed 22 Jun 2014).,Non-OADS,/arxiv_data1/oa_pdf/86/d2/bmjopen-2014-005480.PMC4179568.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 006054).,Non-OADS,/arxiv_data1/oa_pdf/85/bf/bmjopen-2014-006054.PMC4179570.pdf
Data sharing statement Extra data can be accessed via the Dryad data repository at http://datadryad.org/ with the doi:10.5061/dryad.qv4bt.,OADS,/arxiv_data1/oa_pdf/85/bf/bmjopen-2014-006054.PMC4179570.pdf
[cited 2014 03/03/2014]; 69. http://www.aihw.gov.au/medical-workforce/ 28.,OADS,/arxiv_data1/oa_pdf/85/bf/bmjopen-2014-006054.PMC4179570.pdf
http://www.phcris.org.au/fastfacts/fact.php?id=6775.,Non-OADS,/arxiv_data1/oa_pdf/85/bf/bmjopen-2014-006054.PMC4179570.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-005359).,Non-OADS,/arxiv_data1/oa_pdf/2c/26/bmjopen-2014-005359.PMC4179574.pdf
"The diagnosis of AECOPD is based on that deﬁned in the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD COPD guideline, updated in2014: From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014.Available from: http://www.goldcopd.org/).",Non-OADS,/arxiv_data1/oa_pdf/2c/26/bmjopen-2014-005359.PMC4179574.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2014-006026).,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/bmjopen-2014-006026.PMC4179576.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/c5/fd/bmjopen-2014-006026.PMC4179576.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-005635).,Non-OADS,/arxiv_data1/oa_pdf/82/f1/bmjopen-2014-005635.PMC4179578.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/82/f1/bmjopen-2014-005635.PMC4179578.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2014-006016).,Non-OADS,/arxiv_data1/oa_pdf/ad/5c/bmjopen-2014-006016.PMC4179580.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/d5/83/bmjopen-2014-006132.PMC4179582.pdf
2011. http://www.who.int/hiv/pub/guidelines/kenya_art.pdf (accessed 7 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/d5/83/bmjopen-2014-006132.PMC4179582.pdf
2009. http://www.who.int/hiv/pub/guidelines/kenya_tb.pdf (accessed 7 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/d5/83/bmjopen-2014-006132.PMC4179582.pdf
http://siteresources.worldbank.org/INTAFRICA/Resources/ 257994-1335471959878/Kenya_County_Fact_Sheets_Dec2011.pdf (accessed 7 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/d5/83/bmjopen-2014-006132.PMC4179582.pdf
To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-005923).,Non-OADS,/arxiv_data1/oa_pdf/7a/4d/bmjopen-2014-005923.PMC4179584.pdf
"Information about the study was posted on the of ﬁcial web page of the clinic (http://www.internetpsykiatri.se), and ﬂyers were distributed to mental health profes- sionals.",Non-OADS,/arxiv_data1/oa_pdf/7a/4d/bmjopen-2014-005923.PMC4179584.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseApril 2014 |  86  | e51686 | Page 1 of 10Video Article Exfoliation of Egyptian Blue and Han Blue, Two Alkali Earth Copper Silicate- based Pigments Darrah Johnson-McDaniel1, Tina T. Salguero1 1Department of Chemistry, The University of Georgia Correspondence to: Tina T. Salguero at salguero@uga.edu URL: http://www.jove.com/video/51686 DOI: doi:10.3791/51686 Keywords: Chemistry, Issue 86, Nanosheets, Egyptian Blue, Han Blue, Pigment, Near Infrared, Luminescence, Exfoliation, Delamination, Two- Dimensional, Ink, Colloidal Dispersion Date Published: 4/24/2014 Citation: Johnson-McDaniel, D., Salguero, T.T.",Non-OADS,/arxiv_data1/oa_pdf/eb/f1/jove-86-51686.PMC4179608.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51686/ Introduction Vibrant colors were prized throughout the ancient world.,Non-OADS,/arxiv_data1/oa_pdf/eb/f1/jove-86-51686.PMC4179608.pdf
"Chamuleau at s.a.j.chamuleau@umcutrecht.nl URL: http://www.jove.com/video/51269 DOI: doi:10.3791/51269 Keywords: Medicine, Issue 86, myocardial infarction (MI), AMI, large animal model, pig, translational medicine, ischemic heart disease Date Published: 4/25/2014 Citation: Koudstaal, S., Jansen of Lorkeers, S.J., Gho, J.M., van Hout, G.P., Jansen, M.S., Gründeman, P.F., Pasterkamp, G., Doevendans, P.A., Hoefer, I.E., Chamuleau, S.A. Myocardial Infarction and Functional Outcome Assessment in Pigs.",Non-OADS,/arxiv_data1/oa_pdf/c9/4b/jove-86-51269.PMC4179618.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/51269/ Introduction Acute myocardial infarction (AMI) and its long-term sequelae such as chronic heart failure (CHF) profoundly impact patient prognosis and quality of life, let alone the high cost restraints imposed on our available healthcare resources1.",Non-OADS,/arxiv_data1/oa_pdf/c9/4b/jove-86-51269.PMC4179618.pdf
"http://informahealthcare.com/nan ISSN: 1743-5390 (print), 1743-5404 (electronic) Nanotoxicology, 2014; 8(S1): 72–84 !2014 Informa UK, Ltd. DOI: 10.3109/17435390.2013.855832 ORIGINAL ARTICLE Dermal absorption and short-term biological impact in hairless mice from sunscreens containing zinc oxide nano- or larger particles Megan J. Osmond-McLeod1, Yalchin Oytam1, Jason K. Kirby2, Laura Gomez-Fernandez3*, Brent Baxter4, and Maxine J. McCall1 1CSIRO Animal, Food and Health Sciences, CSIRO Advanced Materials TCP (Nanosafety), North Ryde, NSW, Australia,2CSIRO Land and Water, CSIRO Advanced Materials TCP (Nanosafety), Waite Campus, Urrbrae, SA, Australia,3CSIRO Earth Science and Resource Engineering, CSIRO Advanced Materials TCP (Nanosafety), North Ryde, NSW, Australia, and4Baxter Laboratories Pty Ltd, Boronia, VIC, Australia Abstract Previous studies have shown no, or very limited, skin penetration of metal oxide nanoparticles following topical application of sunscreens, yet concerns remain about their safety comparedto larger particles.",Non-OADS,/arxiv_data1/oa_pdf/57/95/NAN-08-72.PMC4179643.pdf
"Gene expression data have been deposited at the Gene Expression Omnibus at NCBI (http://www.ncbi.nlm.nih.gov/geo/)under Accession Number: GSE46568 ID 200046568.Transcriptional activity was more greatly perturbed in livers of mice treated with the formulation only (showing a total of 6485differentially transcribed genes compared to no treatment) than for mice treated with the nano or bulk sunscreens (with a total of862 and 118 perturbed genes, respectively, compared to no treatment).",Non-OADS,/arxiv_data1/oa_pdf/57/95/NAN-08-72.PMC4179643.pdf
[Online] Available at: https://www.cosmeticseur- ope.eu/publications-cosmetics-europe-association/guide-lines.html?view=item&id=21.,Non-OADS,/arxiv_data1/oa_pdf/57/95/NAN-08-72.PMC4179643.pdf
[Online] Available at: http://www.iso.org/iso/catalogue_detail.htm?csnumber ¼46579.,Non-OADS,/arxiv_data1/oa_pdf/57/95/NAN-08-72.PMC4179643.pdf
[Online] Available at: http://www.tga.gov.au/pdf/sunscreens-nanoparticles- 2009.pdf.,Non-OADS,/arxiv_data1/oa_pdf/57/95/NAN-08-72.PMC4179643.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/eb/41/ijgm-7-463.PMC4179753.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of General Medicine 2014:7 463–473International Journal of General Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  463OrIGInal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJGM.S6706 5Omega-3 fatty acid supplementation and cognitive  function: are smaller dosages more beneficial?,Non-OADS,/arxiv_data1/oa_pdf/eb/41/ijgm-7-463.PMC4179753.pdf
"International Journal of General Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-general-medicine-journa lThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal  medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat - ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/eb/41/ijgm-7-463.PMC4179753.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/eb/41/ijgm-7-463.PMC4179753.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/55/db/jbm-5-185.PMC4179754.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Blood Medicine 2014:5 185–189Journal of Blood Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  185ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/JBM.S6798 9The relationship between red blood cell  distribution width and blood pressure in patients  with type 2 diabetes mellitus in Lagos, Nigeria Olusola Akinola Dada1 Ebele Uche2 Akinsegun Akinbami2 Majeed Odesanya3 Sarah John-Olabode4 Adewumi Adediran5 Olajumoke Oshinaike1 Anthonia Okeoghene  Ogbera1 Olaitan Okunoye6 Olanrewaju Arogundade2 Kingsley Aile7 Timothy Ekwere8 1Department of Medicine, Lagos  State University, 2Department of  Haematology and Blood Transfusion,   Lagos State University, College  of Medicine, Ikeja, Nigeria; 3Oak  Hospitals, Ikorodu, Lagos, Nigeria;   4Department of Haematology, Ben  Carson School of Medicine, Babcock  University, Ilisan-Remo, Ogun State,   5Department of Haematology,   Faculty of Clinical Sciences, College  of Medicine, University of Lagos,   Idiaraba, 6Department of Medicine,   University of Port Harcourt, River  State, 7Department of Haematology  and Blood Transfusion, Lagos State  University T eaching Hospital, Ikeja,   Nigeria; 8Department of Haematology  and Blood Transfusion, University of  Uyo, Akwa Ibom, Nigeria Correspondence: Ebele Uche   Department of Haematology and Blood  Transfusion, Lagos State University,  College of Medicine, PMB21266, Ikeja,  Lagos, Nigeria   Email eifeyinwa2000@yahoo.co mBackground:  High red blood cell distribution width (RDW) is related to impairment of  erythropoiesis, reflecting chronic inflammation and increased levels of oxidative stress, both of  which are telltale signs of type 2 diabetics.",Non-OADS,/arxiv_data1/oa_pdf/55/db/jbm-5-185.PMC4179754.pdf
"Journal of Blood Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/Journal-of-blood-medicine-journa lThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects  of all topics pertaining to blood based medicine including but not limited to:  Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,  and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of  blood related medicine; Legal aspects of blood medicine; Historical perspec - tives.",Non-OADS,/arxiv_data1/oa_pdf/55/db/jbm-5-185.PMC4179754.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/55/db/jbm-5-185.PMC4179754.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1819–1826Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1819OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/NDT .S6780 5De-chang Peng1 Xi-Jian Dai1,2 hong-han gong1 hai-Jun li1 Xiao Nie1 Wei Zhang3 1Department of radiology, The First  affiliated hospital of Nanchang University,   Jiangxi, 2Department of imaging and  interventional radiology, Prince of Wales  hospital, The chinese University of hong  Kong, shatin,    hong Kong, special administrative region,   3Department of Pneumology, The First  affiliated hospital   of Nanchang University, Jiangxi, People’s  republic of china correspondence: Wei Zhang   Department of Pneumology, The First Affiliated  hospital of Nanchang University, 17 Yong Wai  Zheng street, Donghu District, Nanchang city,  Jiangxi 330006, People’s republic of china   Tel +86 791 8869 2582   email zhangweiliuxin@163.co m altered intrinsic regional brain activity in male  patients with severe obstructive sleep apnea:  a resting-state functional magnetic resonance  imaging studyJournal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Peng et al Running head recto: Resting functional MRI in men with OSA DOI: http://dx.doi.org/10.2147/NDT.S67805 Background:  Previous studies have demonstrated that obstructive sleep apnea (OSA) is  associated with abnormal brain structural deficits.",Non-OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
Or use: http://dvpr.es/1lVgNT 0Video abstract,Non-OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
"On the basis  of MATLAB2010a software (Mathworks, Natick, MA,  USA), the rest of the data preprocessing was performed using  DPARSFA software ( http://rfmri.org/DPARSF ), including  DICOM form transformation, slice timing, head motion  correction, and spatial normalization.",OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
"The six Friston head motion parameters  was used to correct for the effects of head motion based on  recent work showing that higher-order models are more  effective in removing head motion effects.37,38 After cor - rection for head motion, the functional MRI images were  spatially normalized to the Montreal Neurological Institute  space using the standard echo-planar imaging template  in Statistical Parametric Mapping 8 ( http://www.fil.ion.",OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
ReHo computation based  on protocols from previous studies was performed with REST  software ( http://www.resting-fmri.Sourceforge.net ).29  Individual ReHo maps were generated by calculating  Kendall’s coefficient of concordance (KCC) for the time  series of a given voxel with those of its nearest neighbors  (26 voxels) in a voxel-wise analysis.,OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1826Peng et al 20.,Non-OADS,/arxiv_data1/oa_pdf/ef/af/ndt-10-1819.PMC4179755.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5a/b3/dddt-8-1481.PMC4179756.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2014:8 1481–1497Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1481Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S6881 8Ferulago angulata  activates intrinsic pathway  of apoptosis in McF-7 cells associated with  g1 cell cycle arrest via involvement of p21/p27 hamed Karimian1 soheil Zorofchian  Moghadamtousi2 Mehran Fadaeinasab3 shahram golbabapour2 Mahboubeh razavi1 Maryam hajrezaie2 aditya arya1 Mahmood ameen abdulla4 syam Mohan5 hapipah Mohd ali2 Mohamad ibrahim noordin1 1Department of Pharmacy, Faculty  of Medicine, 2institute of Biological  sciences, Faculty of science,   3Department of chemistry,   4Department of Biomedical science,   Faculty of Medicine, University  of Malaya, Kuala lumpur, Malaysia,   5Medical research centre, Jazan  University, Jazan, saudi arabia correspondence: hamed Karimian Department of Pharmacy, Faculty  of Medicine, University of Malaya,  50603 Kuala lumpur, Malaysia Tel +603 7967 7520  Fax +603 7967 4964 email hamedkarimian61@gmail.com Journal name: Drug Design, Development and Therapy Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Karimian et al Running head recto: Apoptotic effect of Ferulago angulata DOI: http://dx.doi.org/10.2147/DDDT.S68818 Abstract:  Ferulago angulata  is a medicinal plant that is traditionally known for its   anti-inflammatory and antiulcer properties.",Non-OADS,/arxiv_data1/oa_pdf/5a/b3/dddt-8-1481.PMC4179756.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDove pres s Drug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/5a/b3/dddt-8-1481.PMC4179756.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/b3/dddt-8-1481.PMC4179756.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f2/03/dddt-8-1429.PMC4179757.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2014:8 1429–1439Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1429Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S6751 8Time and dose relationships between schisandrin  B- and schisandrae fructus oil-induced  hepatotoxicity and the associated elevations   in hepatic and serum triglyceride levels in mice Yi Zhang1 si-Yuan Pan1 shu-Feng Zhou2 Xiao-Yan Wang1 nan sun1 Pei-li Zhu1 Zhu-sheng chu1 Zhi-ling Yu3 Kam-Ming Ko4 1Department of Pharmacology, school  of chinese Materia Medica, Beijing  University of chinese Medicine,   Beijing, People’s republic of china;   2Department of Pharmaceutical  sciences, college of Pharmacy,   University of south Florida, Tampa,   Fl, Usa; 3school of chinese Medicine,   hong Kong Baptist University,   4Division of life science, hong Kong  University of science and T echnology,   hong Kong, People’s republic of  china correspondence: si-Yuan Pan   Department of Pharmacology,   school of chinese Materia Medica,   Beijing University of chinese Medicine,   Beijing 100102, People’s republic   of china   Tel +86 10 8473 8626   Fax +86 10 6472 1242   email siyuan-pan@163.co m    shu-Feng Zhou   Department of Pharmaceutical sciences,  college of Pharmacy, University of south  Florida, Tampa 33612, Fl, Usa   Tel +1 813 974 6276   Fax +1 813 974 9885   email szhou@health.usf.ed uBackground:  Schisandrin B (Sch B), a dibenzocyclooctadiene compound, is isolated from  schisandrae fructus (SF).",Non-OADS,/arxiv_data1/oa_pdf/f2/03/dddt-8-1429.PMC4179757.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/f2/03/dddt-8-1429.PMC4179757.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f2/03/dddt-8-1429.PMC4179757.pdf
Or use: http://dvpr.es/1C0AHA R,Non-OADS,/arxiv_data1/oa_pdf/f2/03/dddt-8-1429.PMC4179757.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b6/be/ott-7-1631.PMC4179759.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2014:7 1631–1639OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1631Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/OTT .S5159 6Profile of selumetinib and its potential   in the treatment of melanoma Dae won Kim Sapna P Patel Department of Melanoma Medical  Oncology, University of Texas MD  Anderson Cancer Center, Houston,   TX, USA Correspondence: Sapna Patel   MD Anderson Cancer Center, Melanoma  Medical Oncology, 1515 Holcombe Blvd,  Unit 0430, Houston, TX 77030, USA   T el +1 713 792 2921   email sppatel@mdanderson.or gAbstract:  The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver  signal in a number of malignancies.",Non-OADS,/arxiv_data1/oa_pdf/b6/be/ott-7-1631.PMC4179759.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/b6/be/ott-7-1631.PMC4179759.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b6/be/ott-7-1631.PMC4179759.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8a/11/ndt-10-1753.PMC4179760.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1753–1762Neuropsychiatric Disease and Treatment Background:  The role of brain metabolites as biological correlates of the intensity, symptoms,  and course of major depression has not been determined.",Non-OADS,/arxiv_data1/oa_pdf/8a/11/ndt-10-1753.PMC4179760.pdf
"Therefore, the significance of determin - ing the correlation of neurobiological findings in MDD with the clinical symptoms, Dove press submit your manuscript | www.dovepress.co m Dove press  1753OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S6470 2No change in N-acetyl aspartate in first episode  of moderate depression after antidepressant  treatment: 1h magnetic spectroscopy study of left  amygdala and left dorsolateral prefrontal cortex Maja Bajs Janović1,3 Petra Kalember2 Špiro Janović1,3 Pero Hrabač2 Petra Folnegović Grošić1 Vladimir Grošić4 Marko Radoš5 Neven henigsberg2,6 1University Department of Psychiatry,   clinical hospital center Zagreb,   Zagreb, 2Polyclinic Neuron, croatian   institute for Brain research,    school of Medicine, University   of Zagreb, Zagreb, 3University North,    Varaždin, 4Psychiatric hospital sveti  ivan, Zagreb, 5University Department  of radiology, clinical hospital center  Zagreb, Zagreb, 6Psychiatric clinic  Vrapče, Zagreb, Croatia Correspondence: Špiro Janović   University Department of Psychiatry,  clinical hospital centre Zagreb,  Kišpatićeva 12, 10000 Zagreb, Croatia   Tel +38 59 1377 7476   Fax +38 5 1456 6858   email sjanovic@gmail.co mJournal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Bajs Janovi ć et al Running head recto: NAA in correlation of antidepressant response DOI: http://dx.doi.org/10.2147/NDT.S64702",Non-OADS,/arxiv_data1/oa_pdf/8a/11/ndt-10-1753.PMC4179760.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/8a/11/ndt-10-1753.PMC4179760.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1762Bajs Janović et al 42.,Non-OADS,/arxiv_data1/oa_pdf/8a/11/ndt-10-1753.PMC4179760.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bb/55/dddt-8-1499.PMC4179762.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2014:8 1499–1513Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1499Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S6617 9Drug-likeness approach of  2-aminopyrimidines   as histamine h3 receptor ligands Bassem sadek1 annemarie schreeb2 Johannes stephan schwed2,3 lilia Weizel2 holger stark3 1Department of Pharmacology and  Therapeutics, college of Medicine  and health sciences, United arab  emirates University, al ain, United  arab emirates;  2Biocenter, institute  of Pharmaceutical chemistry,   Johann-Wolfgang goethe University,   Frankfurt, germany;  3institute  of Pharmaceutical and Medicinal  chemistry, heinrich heine University,   Duesseldorf, germany correspondence: Bassem sadek   Department of Pharmacology and  Therapeutics, college of Medicine and  health sciences, United arab emirates  University, PO Box  17666, al ain,   United arab emirates   Tel +971 3 713 7512  Fax +971 3 767 2033  email bassem.sadek@uaeu.ac.ae     holger stark   institute of Pharmaceutical and   Medicinal chemistry, heinrich heine   University  26.23, room  02.28,   Duesseldorf  40225, germany   Tel +49 211 811 0478  Fax +49 211 811 3359  email stark@hhu.d eAbstract:   A small series of compounds containing derivatives of  2,4-diamino- and   2,4,6-triaminopyrimidine (compounds  2–7) was synthesized and tested for binding affinity to  human histamine H3 receptors (hH3Rs) stably expressed in HEK-293 cells and human H4Rs  (hH4Rs) co-expressed with G αi2 and G β1γ2 subunits in Sf9 cells.",Non-OADS,/arxiv_data1/oa_pdf/bb/55/dddt-8-1499.PMC4179762.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/bb/55/dddt-8-1499.PMC4179762.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/bb/55/dddt-8-1499.PMC4179762.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9b/6a/ppa-8-1299.PMC4179827.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1299–1309Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1299OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S6576 8comparison of one-year clinical outcomes  between intravascular ultrasound-guided versus  angiography-guided implantation of drug-eluting  stents for left main lesions: a single-center analysis  of a 1,016-patient cohort Xiao-Fei gao1,* Jing Kan1,* Yao-Jun Zhang1,2 Jun-Jie Zhang1 nai-liang Tian1 Fei Ye1 Zhen ge1 Ping-Xi Xiao1 Feng chen3 gary Mintz4 shao-liang chen1 1Department of cardiology, nanjing  First hospital, nanjing Medical  University, nanjing, People’s republic  of china; 2Thorax center, erasmus  Medical center, rotterdam, the  netherlands; 3Department of  epidemiology and Biostatistics,   school of Public health, nanjing  Medical University, nanjing, People’s  republic of china; 4Division of  cardiology, cardiovascular research  Foundation, columbia University,   new Y ork, nY, UsA *These authors contributed equally  contributed to this workBackground:  The importance of intravascular ultrasound (IVUS)-guided stenting of the  unprotected left main coronary artery (ULMCA) remains controversial and has not been fully  studied in the subset of patients with ULMCA.",Non-OADS,/arxiv_data1/oa_pdf/9b/6a/ppa-8-1299.PMC4179827.pdf
"Keywords:  unprotected left main, intravascular ultrasound, major adverse cardiac events Introduction In the modern drug-eluting stent (DES) era, percutaneous coronary intervention of  unprotected left main coronary artery (ULMCA) stenosis has been increasing rapidly.1  Percutaneous coronary intervention remains a class IIa2 or IIb3 recommendation in  current practice guidelines because of its higher rates of target vessel revasculariza - tion (TVR) in distal ULMCA bifurcation lesions.4,5 Intravascular ultrasound (IVUS)  overcomes many of the limitations of angiography by providing more accurate correspondence:  shao-liang chen nanjing First hospital of nanjing Medical  University, cardiology Department,  68 changle road, nanjing, Jiangsu 21006,  People’s republic of china Tel +86 25 5166 2002 Fax +86 25 5220 8048 email chmengx@126.co m Journal name: Patient Preference and Adherence Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Gao et al Running head recto: IVUS stenting of ULMCA DOI: http://dx.doi.org/10.2147/PPA.S65768",Non-OADS,/arxiv_data1/oa_pdf/9b/6a/ppa-8-1299.PMC4179827.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/9b/6a/ppa-8-1299.PMC4179827.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cb/f0/ppa-8-1293.PMC4179828.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 1293–1297Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1293Short rePortopen access to scientific and medical research open Access Full text Article http: //dx.doi.org/ 10.2147/PPA.S6881 4A cross-sectional study to assess the feasibility  of a short message service to improve  adherence of outpatients undergoing sedation  gastrointestinal endoscopy in the People’s  republic of China Xiaoqian Deng Ling Ye Yuting Wang tao Zhu  Department of Anesthesiology, West  China hospital of Sichuan University,   Chengdu, Sichuan, People’s republic  of ChinaBackground:  Adherence to the prescribed preparation regimen for patients scheduled for  sedation gastrointestinal endoscopy (SGIE) often fails to meet health care providers’ expecta - tions.",Non-OADS,/arxiv_data1/oa_pdf/cb/f0/ppa-8-1293.PMC4179828.pdf
"Keywords:  feasibility, short message service, adherence, sedation gastrointestinal  endoscopy Introduction The lack of outpatient adherence to pre-procedural instructions of medical staff has  caused significant concerns regarding the safety and efficient completion of clinical  procedures.1 Although all of the best interventions and efforts are provided by health  care professionals, it is challenging for medical staff to provide in-depth pre-procedural Correspondence: tao Zhu Department of Anesthesiology,  West China hospital of Sichuan  University, Chengdu, Sichuan Province,  610041, People’s republic of China tel +86 189 8060 1552 Fax +86 028 8542 3593 email tao_zhu2013@163.co m Journal name: Patient Preference and Adherence Article Designation: Short Report Y ear: 2014 Volume: 8 Running head verso: Deng et al Running head recto: Feasibility of SMS for outpatients of People’s Republic of China DOI: http://dx.doi.org/10.2147/PPA.S68814",Non-OADS,/arxiv_data1/oa_pdf/cb/f0/ppa-8-1293.PMC4179828.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/cb/f0/ppa-8-1293.PMC4179828.pdf
Available from: http://www.cnnic.,Non-OADS,/arxiv_data1/oa_pdf/cb/f0/ppa-8-1293.PMC4179828.pdf
Available  from: http://www.miit.gov.cn/n11293472/n11293832/n112941341232/ n12858447/14183336.html.,Non-OADS,/arxiv_data1/oa_pdf/cb/f0/ppa-8-1293.PMC4179828.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/38/10/opth-8-1859.PMC4179829.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1859–1867Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1859Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S6988 3surgical treatment for medically refractory  myasthenic blepharoptosis Yusuke shimizu1 shigeaki suzuki2 T omohisa nagasao1 hisao Ogata1 Masaki Yazawa1 norihiro suzuki2 Kazuo Kishi1 1Department of Plastic and  reconstructive surgery, 2Department  of neurology, Keio University school  of Medicine, T okyo, JapanPurpose:  Currently, only a few reports have recommended surgery as a suitable treatment  for blepharoptosis associated with myasthenia gravis.",Non-OADS,/arxiv_data1/oa_pdf/38/10/opth-8-1859.PMC4179829.pdf
"Moreover, while  corticosteroids are very effective in the short term, long-term adverse effects occur in  up to 38% of cases.11,12 Thus, neurologists often struggle to treat patients with medi - cally refractory longstanding blepharoptosis.13–15 Correspondence: Yusuke shimizu Department of Plastic and reconstructive  surgery, Keio University school of  Medicine, 35 shinanomachi, shinjuku,  Tokyo 160-8582, Japan Tel +81 3 5363 3814 Fax +81 3 3352 1054 email yyssprs@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Shimizu et al Running head recto: Surgery for myasthenic blepharoptosis DOI: http://dx.doi.org/10.2147/OPTH.S69883",Non-OADS,/arxiv_data1/oa_pdf/38/10/opth-8-1859.PMC4179829.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/38/10/opth-8-1859.PMC4179829.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/38/10/opth-8-1859.PMC4179829.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pCancer Management and Research 2014:6 365–371Cancer Management and Research Dove press submit your manuscript | www.dovepress.co m Dove press  365ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CMAR.S6724 9interpreting overall survival results   when progression-free survival benefits exist   in today’s oncology landscape: a metastatic   renal cell carcinoma case study Yiyun Tang1 Paul Bycott1 Örjan Åkerborg2 linus Jönsson2 sylvie negrier3 Connie Chen4 1Pfizer global Research and  Development, la Jolla, C a, Usa;   2Optuminsight, stockholm, sweden;   3Medical Oncology Department,   University of lyon, lyon, France;   4Pfizer global Outcomes Research,   new Y ork, nY, Usa Correspondence: Örjan Åkerborg   Klarabergsviadukten 90, hus D,   se-111 64 stockholm, sweden   Tel +46 8 5452 8770   Fax +46 8 5452 8549   email oerjan.akerborg@optum.co mBackground:  The debate surrounding the acceptance of progression-free survival (PFS) as an  intermediate endpoint to overall survival (OS) has grown in recent years, due to the challenges  in demonstrating an OS benefit within clinical trials today.",Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
Available  from: http://www.nccn.org/professionals/physician_gls/PDF/kidney.,Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
"Cancer Management and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/cancer-management-and-research-journa lCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of  preventative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
"Available  from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/ risksharing_oncology_012011_en.pd f. Accessed August 9, 2014.",Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
Available from: http://www.nice.org.,Non-OADS,/arxiv_data1/oa_pdf/5c/f8/cmar-6-365.PMC4179830.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bb/58/clep-6-309.PMC4179833.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2014:6 309–331Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  309REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CLEP .S6888 9Global prevalence and incidence   of traumatic spinal cord injury Anoushka Singh* Lindsay T etreault* Suhkvinder Kalsi-Ryan Aria Nouri Michael G Fehlings T oronto western Research institute,   T oronto western Hospital, T oronto,   Ontario, Canada *These authors contributed equally   to this paper Correspondence: Michael G Fehlings   Division of Neurosurgery, Toronto  western Hospital,  399 Bathurst   St Suite  4ww-449, Toronto   Ontario M5T2S8, Canada   Tel +416 603 5072  Fax 416 603 5298  Email michael.fehlings@uhn.c aBackground:  Spinal cord injury (SCI) is a traumatic event that impacts a patient’ s physical,  psychological, and social well-being and places substantial financial burden on health care  systems.",Non-OADS,/arxiv_data1/oa_pdf/bb/58/clep-6-309.PMC4179833.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access  journal focusing on disease and drug epidemiology, identification of  risk factors and screening procedures to develop optimal preventative  initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/bb/58/clep-6-309.PMC4179833.pdf
"Small (< 150 bp) DNAs or RNAs (e.g., miRNAs, piRNAs, degraded  *Correspondence to: Andrey Turchinovich; Email: a.turchinovich@dkfz.de Submitted: 03/06/2014; Revised: 05/15/2014; Accepted: 05/21/2014; Published Online: 06/12/2014http://dx.doi.org/10.4161/rna.29304Capture and Amplification by Tailing and  Switching (CATS) An ultrasensitive ligation-independent method for  generation of DNA libraries for deep sequencing from  picogram amounts of DNA and RNA andrey t urchinovich1,2,*,†, harald Surowy1,2,†, andrius Serva3, Marc Zapatka3, peter Lichter3, and Barbara Burwinkel1,2 1Molecular e pidemiology; German c ancer r esearch c enter DKFZ; h eidelberg, Germany; 2Molecular Biology of Breast c ancer; University Women`s c linic; h eidelberg, Germany;  3Molecular Genetics; German c ancer r esearch c enter DKFZ; h eidelberg, Germany †these authors contributed equally to this work Massive parallel sequencing (M pS) technologies have paved the way into new areas of research including individualized  medicine.",Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
"Quality trimming (Q20) was performed using the FastX toolkit (version 0.0–13, http://hannonlab.cshl.edu/fastx_toolkit/index.html).",OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Methods 2013; 10:623- 9; PMID:23685885 ; http://dx.doi.org/10.1038/ nmeth.2483 2.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Methods   2014 ; 11:41-6; PMID:24141493 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Methods  2013 ; 10:1096 -8; PMID:24056875 ;  http://dx.doi.org/10.1038/nmeth.2639 7.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Protoc   2014 ; 9:171-81; PMID:24385147 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Genomics  2006 ; 88:127- 31; PMID:16457984 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
BMC Genomics   2010 ; 11:413; PMID:20598146 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nucleic Acids Res 2013 ; 41:e44; PMID:23180801 ;  http://dx.doi.org/10.1093/nar/gks1128 11.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nucleic Acids Res 2006 ; 34:5402 -15;  PMID:17012276 ; http://dx.doi.org/10.1093/nar/ gkl655 12.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Methods Mol Biol  2013 ;  1024 :97-107; PMID:23719945 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Cytogenet Genome  Res 2005 ; 110:462-7; PMID:16093699 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
BMC Genomics   2012 ; 13:341; PMID:22827831 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Methods  2012 ; 9:145-51; PMID:22290186 ;  http://dx.doi.org/10.1038/nmeth.1828 16.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Bioinformatics  2011 ; 27:1571 -2; PMID:21493656 ;  http://dx.doi.org/10.1093/bioinformatics/btr16717.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
PLoS One  2012 ; 7:e51009 ; PMID:23251414 ;  http://dx.doi.org/10.1371/journal.pone.0051009 18.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Sci Transl Med  2012 ; 4:36ra68 ; PMID:22649089 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nature  2013 ; 497:108-12; PMID:23563269 ;  http://dx.doi.org/10.1038/nature12065 23.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
N Engl J Med 2013 ; 368:1249 - 50; PMID:23484798 ; http://dx.doi.org/10.1056/ NEJMe1301249 24.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
J  Clin Oncol  2004 ; 22:4632 -42; PMID :15542813 ;  http://dx.doi.org/10.1200/JCO.2004.07.151 27.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
RNA Biol   2013 ; 10:502-15; PMID:23558773 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Cell Rep  2012 ; 2:666-73;  PMID:22939981 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Biotechnol  2012 ; 30:777-82; PMID:22820318 ;  http://dx.doi.org/10.1038/nbt.228231.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Genome Res 2012 ; 22:125-33;  PMID:22090378 ; http://dx.doi.org/10.1101/ gr.124016.111 32.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Methods  2012 ; 9:357- 9; PMID:22388286 ; http://dx.doi.org/10.1038/ nmeth.1923 33.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Bioinformatics  2009 ; 25:2078 -9; PMID:19505943 ;  http://dx.doi.org/10.1093/bioinformatics/btp352 34.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Genome Biol  2013 ; 14:R36;  PMID:23618408 ; http://dx.doi.org/10.1186/ gb-2013-14-4-r36 35.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Genome Res 2012 ; 22:1760 -74; PMID:22955987 ;  http://dx.doi.org/10.1101/gr.135350.11136.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat  Biotechnol  2010 ; 28:511-5; PMID:20436464 ;  http://dx.doi.org/10.1038/nbt.1621 37.,Non-OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Nat Protoc  2012 ; 7:562-78; PMID:22383036 ;  http://dx.doi.org/10.1038/nprot.2012.016 38.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Genome Biol   2011 ; 12:R22; PMID:21410973 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
Genome Res  2009 ; 19:2317 -23; PMID:19819907 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e4/37/rna-11-817.PMC4179956.pdf
"10,11 Just recently  * Correspondence to: Gabriele Klug1; E-mail: Gabriele.Klug@mikro.bio.uni-giessen.de Submitted: 02/11/2014; Revised: 05/26/2014; Accepted: 06/03/2014; Published Online: 06/12/2014  http://dx.doi.org/10.4161/rna.29440RNase J is required for processing of a small  number of RNAs in Rhodobacter sphaeroides tom r ische-Grahl1, Lennart Weber1, Bernhard r emes1, Konrad U. Förstner2,3, Gabriele Klug1,* 1 Institut für Mikrobiologie und Molekularbiologie, University of Giessen, Germany; 2 Institute for Molecular Infection Biology, University of Würzburg, 97080 Würzburg,  Germany; 3 research c enter for Infectious Diseases, University of Würzburg, 97080 Würzburg, Germany Keywords:  RNase J, RNA decay, ribosome degradation all bacteria contain multiple exoribonucleases to ensure a fast breakdown of different r Na molecules, either for  maturation or for complete degradation to the level of mononucleotides.",Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
"61 and visualized using the Integrated Genome  Browser.29 The raw, de-multiplexed reads as well as coverage files  have been deposited in the National Center for Biotechnology Information’s Gene Expression Omnibus under the accession number GSE54750 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54750).",OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Prog Mol Biol Transl Sci  2009; 85:369-91;  PMID:19215777 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Prog Mol Biol Transl Sci 2009; 85:275-317;  PMID:19215775 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
RNA 2011; 17:338- 45; PMID:21135037 ; http://dx.doi.org/10.1261/ rna.2448911 7.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Proc Natl Acad Sci U S A 1986; 83:120- 4; PMID:2417233 ; http://dx.doi.org/10.1073/ pnas.83.1.120 8.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
The vacB gene required for virulence in Shigella  flexneri and Escherichia coli encodes the exoribo - nuclease RNase R. J Biol Chem 1998; 273:14077-80; PMID:9603904 ; http://dx.doi.org/10.1074/ jbc.273.23.14077 9.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Substrate recognition  and catalysis by the exoribonuclease RNase R. J  Biol Chem 2006; 281:29769-75; PMID:16893880 ;  http://dx.doi.org/10.1074/jbc.M606744200 11.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Proc Natl Acad Sci U S A 2005; 102:16590- 5; PMID:16275923 ; http://dx.doi.org/10.1073/ pnas.0500994102 12.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
J Bacteriol 2012; 194:3883- 90; PMID:22609921 ; http://dx.doi.org/10.1128/ JB.06554-11 13.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Proc Natl Acad Sci U S A 1999; 96:4372-7; PMID:10200269 ; http://dx.doi.org/10.1073/ pnas.96.8.4372 15.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Cell  2002; 111:611-3;  PMID:12464173 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
RNA  2011; 17:99-107;  PMID:21115637 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Cell 2007; 129:681- 92; PMID:17512403 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
J Bacteriol 2013; 195:2340-8;  PMID:23504012 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
"Even S, Pellegrini O, Zig L, Labas V, Vinh J,  Bréchemmier-Baey D, Putzer H. Ribonucleases J1 and J2: two novel endoribonucleases in B.subtilis  with functional homology to E.coli RNase E. Nucleic  Acids Res 2005; 33:2141-52; PMID :15831787 ;  http://dx.doi.org/10.1093/nar/gki505 21.",OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
PLoS Genet 2012; 8:e1002520;  PMID:22412379 ; http://dx.doi.org/10.1371/jour - nal.pgen.1002520 22.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
EMBO J 2009; 28:3523- 33; PMID:19779461 ; http://dx.doi.org/10.1038/ emboj.2009.283 23.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Mol Cell  2011; 43:940-9;  PMID:21925382 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Mol Microbiol 2007; 63:127-38; PMID:17229210 ;  http://dx.doi.org/10.1111/j.1365-2958.2006.05499.x 25.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Mol Microbiol 2011; 82:1260-76; PMID:22014150 ;  http://dx.doi.org/10.1111/j.1365-2958.2011.07888.x 26.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
"Rische T, Klug G. The ordered processing of inter - vening sequences in 23S rRNA of Rhodobacter  sphaeroides requires RNase J. RNA Biol 2012; 9:343- 50; PMID:22336705 ; http://dx.doi.org/10.4161/ rna.1943328.",OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nature 2010; 464:250-5; PMID:20164839 ;  http://dx.doi.org/10.1038/nature08756 29.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Bioinformatics 2009; 25:2730-1;  PMID:19654113 ; http://dx.doi.org/10.1093/ bioinformatics/btp472 30.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Brief Bioinform 2013; 14:193-202;  PMID:22445902 ; http://dx.doi.org/10.1093/bib/ bbs012 31.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
"Li de la Sierra-Gallay I, Zig L, Jamalli A, Putzer  H. Structural insights into the dual activity of RNase J. Nat Struct Mol Biol 2008; 15:206-12;  PMID:18204464 ; http://dx.doi.org/10.1038/ nsmb.1376 32.",OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nucleic Acids Res 2013; 41:7522-35;  PMID:23771137 ; http://dx.doi.org/10.1093/nar/ gkt513 34.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nat Struct Biol 2003; 10:104-8;  PMID:12514741 ; http://dx.doi.org/10.1038/nsb886 35.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
BMC Bioinformatics  2002; 3:2;  PMID:11869452 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Genome Biol 2007; 8:R22; PMID:17313685 ; http://dx.doi.org/10.1186/ gb-2007-8-2-r22 37.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
PLoS One 2013; 8:e76569;  PMID:24116119 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
J Bacteriol 2000; 182:2422-7;  PMID:10762241 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nucleic Acids Res  2003; 31:3406-15;  PMID:12824337 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nucleic Acids Res 2000; 28:1139- 44; PMID:10666455 ; http://dx.doi.org/10.1093/ nar/28.5.1139 41.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
RNA Biol  2013; 10:627-35;  PMID:23580162 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
RNA 2004; 10:899- 906;  PMID :15146073 ; http://dx.doi.org/10.1261/ rna.5242304 43.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Proc Natl Acad Sci U S A 2000; 97:11966- 71; PMID:11035800 ; http://dx.doi.org/10.1073/ pnas.220295997 44.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
J  Biol Chem 2008; 283:17158-67; PMID:18445592 ;  http://dx.doi.org/10.1074/jbc.M801461200 45.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
RNA Biol 2010; 7:316-21; PMID:20458164 ;  http://dx.doi.org/10.4161/rna.7.3.11913 46.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Quality control of ribo - somal RNA mediated by polynucleotide phosphory - lase and RNase R. Proc Natl Acad Sci U S A 2003; 100:6388-93;  PMID:12743360 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Mol Microbiol 2005; 57:318-25;  PMID :15978067 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Cell 1980;  19:393-401;  PMID : 6153577 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
J Mol Biol  1986; 187:23-32;  PMID:3007765 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Mol Microbiol 2010; 75:413-25; PMID:19943899 ;  http://dx.doi.org/10.1111/j.1365-2958.2009.06986.x 51.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nucleic Acids Res 2011; 39:2918-30;  PMID:21138960 ; http://dx.doi.org/10.1093/nar/ gkq1239 52.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nucleic Acids Res 2005; 33:1040-50; PMID :15718303 ; http://dx.doi.org/10.1093/nar/ gki256 54.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
EMBO J 2012; 31:4005-19; PMID:22922465 ;  http://dx.doi.org/10.1038/emboj.2012.229 55. van Niel CB.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Gene 1982; 19:259-68;  PMID:6295879 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Mol Gen Genet 1988; 212:27-37; PMID:2836706 ;  http://dx.doi.org/10.1007/BF00322441 58.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
PLoS Genet  2013; 9:e1003576;  PMID:23818867 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
PLoS  Comput Biol 2009; 5:e1000502; PMID:19750212 ;  http://dx.doi.org/10.1371/journal.pcbi.100050261.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
PLoS Genet 2013; 9:e1003495; PMID:23696746 ;  http://dx.doi.org/10.1371/journal.pgen.1003495 62.,Non-OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
Nucleic Acids Res  2002; 30:207-10;  PMID:11752295 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/02/ad/rna-11-855.PMC4179960.pdf
"However, only a few of these proteins have been charac - terized to date.11 In T. cruzi , TcZFP1 has been shown to bind  preferentially to C-rich regions,12 whereas TcZFP2 has a higher  affinity for A-rich regions and the mRNAs associated with this protein appear to be upregulated in metacyclic trypomastigotes,  *Correspondence to: Samuel Goldenberg; Email address: sgoldenb@fiocruz.br Submitted: 04/21/2014; Revised: 06/15/2014; Accepted: 06/17/2014; Published Online: 07/24/2014 http://dx.doi.org/10.4161/rna.29622The mRNAs associated to a zinc finger protein   from Trypanosoma cruzi shift   during stress conditions Lysangela r onalte a lves, Camila Oliveira, p atricia a lves Mörking, r afael Luis Kessler, Sharon t oledo Martins, Bruno a ccioly  alves r omagnoli, Fabricio Kerrynton Marchini, Samuel Goldenberg* Instituto Carlos Chagas, Fiocruz – pr , Curitiba, p arana, Brazil Keywords: Trypanosoma cruzi , gene expression, mRNPs, regulon, zinc finger, stress response, posttranscriptional regulation trypanosome gene expression is regulated almost exclusively at the posttranscriptional level, through m rNa stabil - ity, storage and degradation.",Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
"926 rNa Biology Volume 11 Issue 7after the CDS stop codon, using the motif discovery software of  RSAT (Regulatory Sequence Analysis Tools - http://rsat.bigre.ulb.ac.be/).",OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
"Functional annotation and the search for regulatory elements For Gene Ontology term enrichment analysis for the classi - fication of transcripts and for Kegg pathway map analysis, 61 we  used the DAVID Annotation tool (http://david.abcc.ncifcrf.gov).",OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
We searched for regulatory elements in the 3 ′ UTR of  the transcripts with RSAT - Regulatory Search Analysis Tools version 1.168 (http://rsat.ulb.ac.be/).,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Curr Pharm Des 2002; 8:269-85; PMID:11860366 ;  http://dx.doi.org/10.2174/1381612023396276 2.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
An Acad Bras Cienc 2008; 80:157-66;   PMID:18345384 ; http://dx.doi.org/10.1590/ S0001-37652008000100011 4.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Biochem Parasitol 2006;  146:135-41;  PMID:16427709 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Adv Parasitol 2011;  75:285-305;  PMID:21820561 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Biochem Parasitol 2007; 156:93-101;   PMID:17765983 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
FEBS Lett 2008; 582:1977-86; PMID:18342629 ;  http://dx.doi.org/10.1016/j.febslet.2008.03.004 9.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nat Rev Genet 2007; 8:533-43;   PMID:17572691 ; http://dx.doi.org/10.1038/nrg2111 11.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
BMC Genomics  2010; 11:283;  PMID:20444260 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mem Inst Oswaldo Cruz 2012; 107:790-9;   PMID:22990970 ; http://dx.doi.org/10.1590/ S0074-02762012000600014 14.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Biochem Biophys  Res Commun 2005; 333:1017-25; PMID:15964555 ;  http://dx.doi.org/10.1016/j.bbrc.2005.06.007 15.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Microbiol 2005;  57:706-16;  PMID:16045615 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Biochem Parasitol 2012; 183:184-8;  PMID:22366391 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Biochem Parasitol 2011; 177:148-51;  PMID:21354218 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J  Biol Chem 2006; 281:39002-13; PMID:17043361 ;  http://dx.doi.org/10.1074/jbc.M604280200 19.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J Biol Chem 2011;  286:20152-62;  PMID:21467035 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nucleic Acids Res  2012; 40:2869-83;  PMID:22140102 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
FEBS Lett 1985; 180:265-70; PMID:2857136 ;  http://dx.doi.org/10.1016/0014-5793(85)81083-8 22.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nat Rev  Mol Cell Biol 2002; 3:195-205; PMID:11994740 ;  http://dx.doi.org/10.1038/nrm760 23.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Gene 2010; 452:72- 8; PMID:20060445 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Cell Biol  2001; 21:4453-9;  PMID:11416125 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
FEBS J  2009; 276:5381-9;  PMID:19712108 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nucleic Acids Res  2002; 30:1427-64;  PMID:11917006 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nature 2003; 424:685-9; PMID:12894212 ; http://dx.doi.org/10.1038/ nature01887 29.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Cell Stress Chaperones 2002;  7:213-21;  PMID:12380690 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Biochem Biophys  Res Commun 2007; 356:1062-7; PMID:17399688 ;  http://dx.doi.org/10.1016/j.bbrc.2007.03.10431.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
FEBS J 2010; 277:3415-26; PMID:20629747 ;  http://dx.doi.org/10.1111/j.1742-4658.2010.07747.x 32.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
BMC Genomics 2009; 10:495;  PMID:19857263 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
"J Biol 2009; 8:100; PMID:20017896 ;  http://dx.doi.org/10.1186/jbiol203 35. de Godoy LM, Marchini FK, Pavoni DP, Rampazzo  RdeC, Probst CM, Goldenberg S, Krieger MA.",OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Proteomics 2012; 12:2694-703; PMID:22761176 ; http://dx.doi.org/10.1002/ pmic.201200078 36.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
"Nucleic Acids Res 2006; 34:5312-24; PMID:17012283 ;  http://dx.doi.org/10.1093/nar/gkl598 37. van Helden J, Rios AF, Collado-Vides J. Discovering regulatory elements in non-coding sequences by  analysis of spaced dyads.",OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nucleic Acids Res 2000;  28:1808-18;  PMID:10734201 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J Cell Biol 1999; 147:1431-42;  PMID:10613902 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Cell 2009; 36:932- 41; PMID:20064460 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Curr Biol  2009; 19:R397-8;  PMID:19467203 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J Biol Chem 2009; 284:35015-28;  PMID :19801539 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol Microbiol 2007;  65:655-70;  PMID:17635187 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mol  Biochem Parasitol 1985; 16:315-27; PMID:3903496 ;  http://dx.doi.org/10.1016/0166-6851(85)90073-8 46.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J Cell Biol 1988;  106:1349-58;  PMID :3283152 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Trends Endocrinol Metab  2007; 18:190-8;  PMID:17500006 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J Neurosci 2008; 28:12581- 90; PMID:19020050 ; http://dx.doi.org/10.1523/ JNEUROSCI.3338-08.2008 50.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Mitochondrion  2009; 9:471-80;  PMID:19703590 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
PLoS Biol 2004; 2:E79; PMID:15024427 ;  http://dx.doi.org/10.1371/journal.pbio.0020079 52.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Anal Chem 2003; 75:663-70; PMID:12585499 ; http://dx.doi.org/10.1021/ ac026117i 54.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Cell 2006; 127:635-48; PMID:17081983 ;  http://dx.doi.org/10.1016/j.cell.2006.09.026 55.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nat Biotechnol 2008; 26:1367-72; PMID:19029910 ;  http://dx.doi.org/10.1038/nbt.1511 56 .,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J  Proteome Res 2011; 10:1794-805; PMID:21254760 ;  http://dx.doi.org/10.1021/pr101065j 57.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nucleic  Acids Res 2010; 38:D457-62; PMID:19843604 ;  http://dx.doi.org/10.1093/nar/gkp851,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Stat Appl Genet Mol  Biol 2004; 3:e3; PMID:16646809 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Bioinformatics  2003; 19:1477-83;  PMID:12912827 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nucleic Acids Res 2000; 28:27-30; PMID:10592173 ; http://dx.doi.org/10.1093/ nar/28.1.2762.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nat Protoc  2009; 4:44-57;  PMID:19131956 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
J Mol Biol 1998; 281:827-42;  PMID:9719638 ; http://dx.doi.org/10.1006/ jmbi.1998.1947 64.,Non-OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Nucleic Acids Res 2011; 39:W86-91;  PMID :21715389 ; http://dx.doi.org/10.1093/nar/ gkr37765.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Clin Chem 2009; 55:611- 22; PMID:19246619 ; http://dx.doi.org/10.1373/ clinchem.2008.112797 66.,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
Methods 2001; 25:402- 8; PMID:11846609 ; http://dx.doi.org/10.1006/ meth.2001.1262,OADS,/arxiv_data1/oa_pdf/5a/68/rna-11-921.PMC4179965.pdf
"Submitted: 04/04/2014; Revised: 06/16/2014; Accepted: 06/30/2014; Published Online: 07/24/2014 http://dx.doi.org/10.4161/rna.29780The Pet309 pentatricopeptide repeat motifs  mediate efficient binding to the mitochondrial  COX1  transcript in yeast angélica Zamudio-Ochoa†, yolanda c amacho-Villasana†, aldo e  García-Guerrero, Xochitl p érez-Martínez*.",Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nature 2011;  478:269-73;  PMID:21947009 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nat Struct Mol Biol  2013 ;  20:1377 -82; PMID:24186060 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Biol Evol  2008 ; 25:1120 - 8; PMID:18343892 ; http://dx.doi.org/10.1093/ molbev/msn0577.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant Cell   2004 ; 16:2089 -103; PMID:15269332 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Trends Plant Sci 2008 ; 13:663-70;  PMID:19004664 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Cell   2011 ; 42:106-17; PMID:21474072 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Biol Chem 2011 ;  286:21361 -71; PMID:21504904 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Biol Chem 2006 ; 281:37661 -7; PMID :17015439 ;  http://dx.doi.org/10.1074/jbc.M608184200 12.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
EMBO J 2009 ; 28:2042 -52; PMID:19424177 ;  http://dx.doi.org/10.1038/emboj.2009.121 13.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Biochem J  2012 ; 441:275- 83; PMID :21880015 ; http://dx.doi.org/10.1042/ BJ20110985 16.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nucleic Acids Res 2012 ; 40:3092 -105;  PMID:22156165 ; http://dx.doi.org/10.1093/nar/ gkr1137 17.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Cell Biol  2008 ; 28:5337 - 47; PMID:18591259 ; http://dx.doi.org/10.1128/ MCB.00563-08 18.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant Cell   2005 ; 17:2791 -804; PMID:16141451 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nat Struct Mol Biol  2013 ; 20:127- 33; PMID:23222640 ; http://dx.doi.org/10.1038/ nsmb.2468 20.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant J  2004 ;  38:152-63; PMID :15053768 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant Physiol  2006 ; 141:825-39;  PMID:16825340 ; http://dx.doi.org/10.1104/ pp.106.07782623.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Biol Evol  2011 ; 28:2935 - 48; PMID:21546354 ; http://dx.doi.org/10.1093/ molbev/msr120 24.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nucleic Acids Res 2001 ; 29:3631 - 7; PMID:11522833 ; http://dx.doi.org/10.1093/ nar/29.17.3631 26.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Genetics   2007 ; 175:1105 -15; PMID:17194787 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Genetics  2010 ; 184:959- 73; PMID:20124025 ; http://dx.doi.org/10.1534/ genetics.110.113969 28.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Biol Chem 2009 ;  284:34116 -25; PMID:19843529 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Curr Top Med Chem  2008 ; 8:1335 -50; PMID:18991722 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Biol Chem 2008 ; 283:1472 -9; PMID:18039654 ;  http://dx.doi.org/10.1074/jbc.M70843720036.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nucleic Acids Res 2011 ; 39:8029 - 41; PMID:21727087 ; http://dx.doi.org/10.1093/nar/ gkr511 37.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Gen Appl Microbiol 2008 ; 54:317- 25; PMID:19164874 ; http://dx.doi.org/10.2323/ jgam.54.317 40.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
BMC Bioinformatics   2007 ; 8:2; PMID:17199898 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Microbiol  2005 ;  56:1689 -704; PMID:15916616 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Biol Cell  2010 ;  21:1937 -44; PMID:20427570 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Cell 2009 ; 138:e1; PMID:19766574 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
EMBO J  2003 ; 22:5951 -61; PMID:14592991 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
EMBO J  2004 ; 23:3472 -82; PMID:15306853 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant Mol Biol   2000 ; 42:603-13; PMID:10809006 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Trends  Biochem Sci  2000 ; 25:46-7; PMID:10664580 ;  http://dx.doi.org/10.1016/S0968-0004(99)01520-0 49.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nucleic Acids Res  2008 ; 36:2958 -68; PMID:18388132 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Biol Chem 2001 ; 276:8616 -22;  PMID:11118450 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Yeast  2009 ; 26:423-40;  PMID:19536766 ; http://dx.doi.org/10.1002/ yea.1672 53.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Biol Cell   2003 ; 14:324-33; PMID:12529447 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Cell Biol  2003 ; 23:4972 -82;  PMID:12832482 ; http://dx.doi.org/10.1128/ MCB.23.14.4972-4982.2003 55.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant J  2012 ; 72:547-58; PMID:22708543 ;  http://dx.doi.org/10.1111/j.1365-313X.2012.05081.x 57.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Cell 2001 ; 105:281- 9; PMID:11336677 ; http://dx.doi.org/10.1016/ S0092-8674(01)00318-X58.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Biol Cell  2010 ; 21:1315 -23;  PMID:20200222 ; http://dx.doi.org/10.1091/mbc.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Proc Natl Acad Sci U S A 2012 ; 109:E1453 -61;  PMID:22566615 ; http://dx.doi.org/10.1073/ pnas.1121465109 60 .,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant Cell   2012 ; 24:3684 -94; PMID:23001034 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
J Biol Chem 2008 ;  283:3767 -72; PMID:18086665 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Plant Cell  2013 ; 25:2265 -75;  PMID:23735295 ; http://dx.doi.org/10.1105/ tpc.113.111567 63.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
PLoS Genet  2012 ; 8:e1002910 ; PMID:22916040 ;  http://dx.doi.org/10.1371/journal.pgen.1002910 64.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
PLoS One   2013 ; 8:e57286 ; PMID:23472078 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Mol Biol Cell   2007 ; 18:523-35; PMID:17135289 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Gene   1989 ; 77:51-9; PMID:2744487 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nucleic Acids Res  1989 ; 17:4535 -9; PMID:2473436 ;  http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
EMBO J 2003 ; 22:3919 -29;  PMID:12881426 ; http://dx.doi.org/10.1093/emboj/ cdg372 73.,Non-OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Methods Cell Biol  2001 ; 65:37-51; PMID:11381604 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Nature   1970 ; 227:680-5; PMID:5432063 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
Methods Cell Biol 2001 ; 65:429- 38; PMID:11381608 ; http://dx.doi.org/10.1016/ S0091-679X(01)65025-8,OADS,/arxiv_data1/oa_pdf/b0/2c/rna-11-953.PMC4179968.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/25/inj-18-103.PMC4180157.pdf
Int Neurourol J 2012;16:1.Editorial  http://dx.doi.org/10.5213/inj.2014.18.3.103 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/c5/25/inj-18-103.PMC4180157.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/52/ce/inj-18-104.PMC4180158.pdf
http://dx.doi.org/10.5858/arpa.2014-0063-ED.,Non-OADS,/arxiv_data1/oa_pdf/52/ce/inj-18-104.PMC4180158.pdf
http://dx.doi.org/10.1586/14737159.2014.929499.,Non-OADS,/arxiv_data1/oa_pdf/52/ce/inj-18-104.PMC4180158.pdf
Int Neurourol J 2014;18:106-14.Editorial  http://dx.doi.org/10.5213/inj.2014.18.3.104 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/52/ce/inj-18-104.PMC4180158.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/53/f7/inj-18-105.PMC4180159.pdf
Editorial  http://dx.doi.org/10.5213/inj.2014.18.3.105 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/53/f7/inj-18-105.PMC4180159.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"Finally, we dis - cuss the future research directions and summarize our findings.Review Article http://dx.doi.org/10.5213/inj.2014.18.3.106 pISSN 2093-4777 · eISSN 2093-6931",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
www.einj.org     107 Fiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ WHAT IS IC?,Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"108    www.einj.orgFiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ cytology, cystoscopy with and without hydrodistention and/or  bladder biopsy, and biofluid-based assays [7,20-22].",OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
www.einj.org     109 Fiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ sample volumes.,OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"The following data - bases could be used: HMDB (http://www.hmdb.ca/), METLIN  (http://metlin.scripps.edu/), MassBank (http://www.massbank.",OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"jp), PubChem (http://ncbi.nim.nih.gov/), and Kyoto Encyclope - dia of Genes and Genomes (http://www.kegg.jp/).",OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"110    www.einj.orgFiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ may play a significant role in IC with regard to early detection,  diagnosis, prognosis, drug development, and sensitivity predic - tion to clinical treatments.",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"www.einj.org     111 Fiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ FUTURE STUDIES  As a future direction, we may consider several studies that  should soon be answered by metabolomics approaches.",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
112    www.einj.orgFiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ ported.,OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
www.einj.org     113 Fiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ Concentrations of specific epithelial growth factors in the urine of  interstitial cystitis patients and controls.,Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
http://dx.doi.org/10.1002/bmc.3219.,Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
114    www.einj.orgFiehn and Kim  •  Metabolic Profiling in Interstitial Cystitis http://dx.doi.org/10.5213/inj.2014.18.3.106INJ approach identifies human urinary phenylacetylglutamine as a  novel marker of interstitial cystitis.,Non-OADS,/arxiv_data1/oa_pdf/8c/4d/inj-18-106.PMC4180160.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
Activated microglia readily undergo dramatic changes in mor - phology and the surface expression of molecules such as major Original Article http://dx.doi.org/10.5213/inj.2014.18.3.115 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ histocompatibility complex, which is recognized by the antibody  to CD11b.",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ down avoidance task was determined, as per the previously de - scribed method [20].",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ Rad).,Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ sults showed that DNA fragmentation in the hippocampal CA1  region was enhanced by the induction of ischemia (P < 0.05), but  that treatment with berberine reduced DNA fragmentation in  the ischemic gerbils (P < 0.05).",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ (23 kDa) in the sham-operation group was set at 1.00, the level of  Bax was 1.65 ± 0.07 in the ischemia-induction group, 1.38 ± 0.15  in the ischemia-induction and 20 mg/kg berberine-treated group,  0.75 ± 0.07 in the ischemia-induction and 50 mg/kg berberine- treated group, and 0.61 ± 0.08 in the ischemia-induction and 80  mg/kg berberine-treated group.",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ 0.46 in the ischemia-induction group, 3.16 ± 0.57 in the ischemia- induction and 20 mg/kg berberine-treated group, 2.70 ± 0.44 in  the ischemia-induction and 50 mg/kg berberine-treated group,  and 1.65 ± 0.24 in the ischemia-induction and 80 mg/kg berber - ine-treated group.",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ [2].,Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ vation have been implicated in the neuronal dysfunction and  cell death [4,7].",Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ ing deficits and hippocampal neuron loss following transient global  cerebral ischemia in rats.,Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
•  Isoquinoline Alkaloid Inhibits Ischemia-Induced Apoptosis http://dx.doi.org/10.5213/inj.2014.18.3.115INJ Pathol 2007;35:495-516.,Non-OADS,/arxiv_data1/oa_pdf/95/70/inj-18-115.PMC4180161.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
"MATERIALS AND METHODS A population-based, cross-sectional door-to-door survey of  men aged ≥40 years was conducted in Korea to examine the Original Article http://dx.doi.org/10.5213/inj.2014.18.3.126 pISSN 2093-4777 · eISSN 2093-6931",Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
•  The Prevalence of LUTS in Korean Men http://dx.doi.org/10.5213/inj.2014.18.3.126INJ prevalence of LUTS.,Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
•  The Prevalence of LUTS in Korean Men http://dx.doi.org/10.5213/inj.2014.18.3.126INJ cal analyses using the statistical software package R ver.,OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
•  The Prevalence of LUTS in Korean Men http://dx.doi.org/10.5213/inj.2014.18.3.126INJ increase with age: from 78.3% for men aged 40–49 years to  89.6% for men aged ≥ 60 years.,Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
"•  The Prevalence of LUTS in Korean Men http://dx.doi.org/10.5213/inj.2014.18.3.126INJ common combination of LUTS (35.2%), and all three categories  of LUTS were reported in 23.5% of respondents when using this  refined definition.",Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
•  The Prevalence of LUTS in Korean Men http://dx.doi.org/10.5213/inj.2014.18.3.126INJ vinced that the method used in the present study increased reli - ability of our data.,Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
SUPPLEMENTARY MATERIAL Supplementary material can be found via http://einj.org/src/sm/ einj-18-126-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
"•  The Prevalence of LUTS in Korean Men http://dx.doi.org/10.5213/inj.2014.18.3.126INJ bidities, lower urinary tract symptoms and sexual function.",Non-OADS,/arxiv_data1/oa_pdf/d5/92/inj-18-126.PMC4180162.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/38/cc/inj-18-133.PMC4180163.pdf
Anticholinergic use  has been discouraged in the past for fear of inducing urinary Original Article http://dx.doi.org/10.5213/inj.2014.18.3.133 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/38/cc/inj-18-133.PMC4180163.pdf
"•  Clinical Outcome in Male Patients With DOIC http://dx.doi.org/10.5213/inj.2014.18.3.133INJ retention in patients with coexisting detrusor failure [1,11].",Non-OADS,/arxiv_data1/oa_pdf/38/cc/inj-18-133.PMC4180163.pdf
"•  Clinical Outcome in Male Patients With DOIC http://dx.doi.org/10.5213/inj.2014.18.3.133INJ  Diaz, et al.",Non-OADS,/arxiv_data1/oa_pdf/38/cc/inj-18-133.PMC4180163.pdf
"•  Clinical Outcome in Male Patients With DOIC http://dx.doi.org/10.5213/inj.2014.18.3.133INJ The clinical presentation is often a result of the complex inter - play between multiple pathophysiological processes: the effect of  an aging bladder, the presence of BOO, and systemic factors  such as polypharmacy and declining cardiovascular and cogni - tive functions.",Non-OADS,/arxiv_data1/oa_pdf/38/cc/inj-18-133.PMC4180163.pdf
"•  Clinical Outcome in Male Patients With DOIC http://dx.doi.org/10.5213/inj.2014.18.3.133INJ  Diaz, et al.",Non-OADS,/arxiv_data1/oa_pdf/38/cc/inj-18-133.PMC4180163.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
Hinman [9] described that the urethral branches of Original Article http://dx.doi.org/10.5213/inj.2014.18.3.138 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
"•  Arterial Anatomy of Prostate During HoLEP http://dx.doi.org/10.5213/inj.2014.18.3.138INJ the prostatic arteries enter near the vesical neck at the 5 and 7  o’ clock positions and constitute the blood supply to the adenoma;   thus, persistent excessive bleeding can be controlled with a pos - terior capsular suture near the neck.",Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
•  Arterial Anatomy of Prostate During HoLEP http://dx.doi.org/10.5213/inj.2014.18.3.138INJ of bleeder was defined as ≥ 10 significant bleeders.,Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
•  Arterial Anatomy of Prostate During HoLEP http://dx.doi.org/10.5213/inj.2014.18.3.138INJ Fig.,Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
"•  Arterial Anatomy of Prostate During HoLEP http://dx.doi.org/10.5213/inj.2014.18.3.138INJ sis, the PSA level, a history of a preoperative biopsy, and postop - erative pathologic findings were associated with the number of  bleeders.",Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
•  Arterial Anatomy of Prostate During HoLEP http://dx.doi.org/10.5213/inj.2014.18.3.138INJ ing the location of bleeders facilitate excellent hemostasis.,Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
•  Arterial Anatomy of Prostate During HoLEP http://dx.doi.org/10.5213/inj.2014.18.3.138INJ al.,Non-OADS,/arxiv_data1/oa_pdf/7e/04/inj-18-138.PMC4180164.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3d/e4/inj-18-145.PMC4180165.pdf
It is presumed that the  central sympathetic overactivity might be associated with the Original Article http://dx.doi.org/10.5213/inj.2014.18.3.145 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/3d/e4/inj-18-145.PMC4180165.pdf
"•  Treatment Efficacy According to Sympathetic Activity http://dx.doi.org/10.5213/inj.2014.18.3.145INJ LUTS in patients with benign prostatic hyperplasia (BPH); it is  associated with metabolic syndrome in men [1,7].",Non-OADS,/arxiv_data1/oa_pdf/3d/e4/inj-18-145.PMC4180165.pdf
•  Treatment Efficacy According to Sympathetic Activity http://dx.doi.org/10.5213/inj.2014.18.3.145INJ RESULTS Baseline Characteristics of the Subjects The mean age of healthy volunteers was 56.2 years.,Non-OADS,/arxiv_data1/oa_pdf/3d/e4/inj-18-145.PMC4180165.pdf
"•  Treatment Efficacy According to Sympathetic Activity http://dx.doi.org/10.5213/inj.2014.18.3.145INJ ing a direct link between the benign prostatic enlargement  (BPE), bladder outlet obstruction (BOO) and LUTS [3].",Non-OADS,/arxiv_data1/oa_pdf/3d/e4/inj-18-145.PMC4180165.pdf
•  Treatment Efficacy According to Sympathetic Activity http://dx.doi.org/10.5213/inj.2014.18.3.145INJ ACKNOWLEDGEMENTS This study was supported by a grant from Ajou University Hos - pital.,Non-OADS,/arxiv_data1/oa_pdf/3d/e4/inj-18-145.PMC4180165.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1d/2e/inj-18-150.PMC4180166.pdf
OAB was diagnosed us -Original Article http://dx.doi.org/10.5213/inj.2014.18.3.150 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/1d/2e/inj-18-150.PMC4180166.pdf
www.einj.org     151 Park and Huh  •  Association Between Hesitancy and Urgency in Women With OAB http://dx.doi.org/10.5213/inj.2014.18.3.150INJ ing questionnaires ( > 8 points of OAB questionnaire) and based  on the definition of the International Continence Society (ICS)  [1].,Non-OADS,/arxiv_data1/oa_pdf/1d/2e/inj-18-150.PMC4180166.pdf
152    www.einj.orgPark and Huh  •  Association Between Hesitancy and Urgency in Women With OAB http://dx.doi.org/10.5213/inj.2014.18.3.150INJ the patients’ quality of life.,Non-OADS,/arxiv_data1/oa_pdf/1d/2e/inj-18-150.PMC4180166.pdf
www.einj.org     153 Park and Huh  •  Association Between Hesitancy and Urgency in Women With OAB http://dx.doi.org/10.5213/inj.2014.18.3.150INJ  Various questionnaires have been developed by researchers to  identify the severity of urinary urgency [11].,Non-OADS,/arxiv_data1/oa_pdf/1d/2e/inj-18-150.PMC4180166.pdf
"154    www.einj.orgPark and Huh  •  Association Between Hesitancy and Urgency in Women With OAB http://dx.doi.org/10.5213/inj.2014.18.3.150INJ obstruction, uroflowmetry is an appropriate method for identi - fying bladder function.",Non-OADS,/arxiv_data1/oa_pdf/1d/2e/inj-18-150.PMC4180166.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
The gradual worsening Original Article http://dx.doi.org/10.5213/inj.2014.18.3.155 pISSN 2093-4777 · eISSN 2093-6931,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJ of LUTS results in further reduction of the QoL [8].,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
"•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJ ing TV , mealtimes, sitting time outside of work hours.",Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJ Table 1.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJTable 2.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJ All of those 8 studies investigated effects for BPH according to PA  intensity and frequency and reported the greater effect with more  intense and frequent PA [11].,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJ ducing sedentary time might weaken statistical power.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
http://dx.doi.org/10.1111/bju.12745.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
•  Physical Activity for Subjects With Prevention of BPH http://dx.doi.org/10.5213/inj.2014.18.3.155INJ 25.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
http://dx.doi.org/10.1007/s40618-014- 0051-3.,Non-OADS,/arxiv_data1/oa_pdf/9e/67/inj-18-155.PMC4180167.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c1/54/inj-18-163.PMC4180168.pdf
"Despite many treatment strategies, there are Original Article http://dx.doi.org/10.5213/inj.2014.18.3.163 pISSN 2093-4777 · eISSN 2093-6931",Non-OADS,/arxiv_data1/oa_pdf/c1/54/inj-18-163.PMC4180168.pdf
•  Efficacy of HA for IC/PBS Patients http://dx.doi.org/10.5213/inj.2014.18.3.163INJ no standard treatment guidelines.,Non-OADS,/arxiv_data1/oa_pdf/c1/54/inj-18-163.PMC4180168.pdf
"•  Efficacy of HA for IC/PBS Patients http://dx.doi.org/10.5213/inj.2014.18.3.163INJ cifically, HA instillation significantly improved voiding symp - toms according to questions 1 and 3 in the ICPI (P < 0.001 and  P = 0.026, respectively) and bladder pain and nocturia according  to questions 2 and 4 in the ICPI (P = 0.026 and P = 0.008, respec - tively).",Non-OADS,/arxiv_data1/oa_pdf/c1/54/inj-18-163.PMC4180168.pdf
•  Efficacy of HA for IC/PBS Patients http://dx.doi.org/10.5213/inj.2014.18.3.163INJ ties were controversial because of the recurrence and the com - plications.,Non-OADS,/arxiv_data1/oa_pdf/c1/54/inj-18-163.PMC4180168.pdf
•  Efficacy of HA for IC/PBS Patients http://dx.doi.org/10.5213/inj.2014.18.3.163INJ report from the standardisation sub-committee of the International  Continence Society.,Non-OADS,/arxiv_data1/oa_pdf/c1/54/inj-18-163.PMC4180168.pdf
"INJ This is an Open Access article distributed under the terms of the Creative Commons Attri - bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/27/b0/inj-18-168.PMC4180169.pdf
Copyright © 2014 Korean Continence Society www.einj.orgInternational Neurourology Journal Int Neurourol J 2014;18:168 http://dx.doi.org/10.5213/inj.2014.18.3.168 pISSN 2093-4777 · eISSN 2093-6931Book Review Trigger point therapy is a  concept that is vaguely under - stood by the medical com - munity outside of those spe - cializing in pain treatment.,Non-OADS,/arxiv_data1/oa_pdf/27/b0/inj-18-168.PMC4180169.pdf
"To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ .",Non-OADS,/arxiv_data1/oa_pdf/bf/d8/nihms628939.PMC4180223.pdf
"Although formal methods are established to perform these tests rigorously, researchers should at the very least evaluate and report the level of background variation in an implicated gene in population cohorts, taking advantage of public resources such as the Exome Variant Server ( http://evs.gs.washington.edu/EVS/ ) when implicating a new gene in pathogenesis.",Non-OADS,/arxiv_data1/oa_pdf/bf/d8/nihms628939.PMC4180223.pdf
"We are hopeful that such activities can be coordinated around the US National Center for Biotechnology Information (NCBI)’s newly launched ClinVar database ( https://www.ncbi.nlm.nih.gov/clinvar/ ), which will also interface with existing efforts in this space including the LOVD (Leiden Open (source) Variation Database)53 and other locus-specific databases, OMIM (Online Mendelian Inheritance in Man; http://omim.org/ ) and DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources)54.",Non-OADS,/arxiv_data1/oa_pdf/bf/d8/nihms628939.PMC4180223.pdf
"Models for successful data sharing efforts in rare disease already exist in the field of copy number variation with the DECIPHER database54 and the International Standards for Cytogenomic Arrays Consortium ( https://www.iscaconsortium.org/ ), aided by an increasing number of rare-disease resource consortia, and several ambitious efforts to establish clear global standards for genomic data sharing are now underway56.",Non-OADS,/arxiv_data1/oa_pdf/bf/d8/nihms628939.PMC4180223.pdf
2013 http://genomicsandhealth.org/files/public/White%20Paper%20June %203%20final.pdf .,OADS,/arxiv_data1/oa_pdf/bf/d8/nihms628939.PMC4180223.pdf
Available at http://www.broadinstitute.org/gsea/ GSEAUserGuide.pdf.,Non-OADS,/arxiv_data1/oa_pdf/12/e4/acn30001-0605.PMC4180413.pdf
"Review Article http://dx.doi.org/10.4070/kcj.2014.44.5.281 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Stroke and Bleeding Risk in Atrial Fibrillation Keitaro Senoo, MD, Deirdre Lane, PhD, and Gregory YH Lip, MD University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinical setting.",Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
"Correspondence: Gregory YH Lip, MD, University of Birmingham Centre  for Cardiovascular Sciences, City Hospital, Birmingham 13187QH, United  KingdomTel: 44 121 50705080, Fax: 44 121 5544083E-mail: g.y.h.lip@bham.ac.uk This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.The purpose of this review is to provide an overview of stroke  and bleeding risk assessment in AF patients.",Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
"282 Stroke and Bleeding Risk in Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org ≥80 years of age.6) Although AF is generally not as immediately life-threatening as  ventricular arrhythmias, patients with AF have increased risks of  stroke and heart failure, and reduced quality of life.7-9) AF leads to a  5-fold increased risk of stroke, and it is estimated that up to 25% of  all strokes in the elderly are a consequence of AF.6) Furthermore, AF- related strokes are more severe, with patients twice as likely to be  bedridden as patients with stroke from other etiologies and more  likely to die.10-12) The mean rate of ischemic stroke among patients with nonvalvu - lar AF is 5% per year, which is 2–7 times that of the general adult  population.9) The risk of stroke increases from 1.5% in patients with  AF aged 50–59 years to 23% in those aged 80–89 years.11) Anti - thrombotic therapy, particularly with warfarin, decreases the risk of  stroke in patients with AF.13)14) Warfarin use is associated with a 64%  risk reduction in stroke and a 26% reduction in all cause mortality,  compared with control or placebo, while aspirin is associated with a  non-significant 19% risk reduction, with no impact on mortality.15) Although AF increases the risk of stroke and thromboembolism  5-fold, this risk is not homogeneous and is altered by the presence  of various stroke risk factors.",Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org In its original validation, the CHA 2DS2-VASc score was compared  with seven other contemporary stroke risk stratification schemas  for 1084 patients in the Euro Heart Survey on AF.",Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
284 Stroke and Bleeding Risk in Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org of cohort person-years.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org NICE guidelines.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
286 Stroke and Bleeding Risk in Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org Table 3.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org Atrial Fibrillation in the Asian Population Both bleeding and thromboembolism rates are generally higher  in Asians than non-Asians because of difficulty in proper usage of  warfarin in Asians.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
288 Stroke and Bleeding Risk in Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org with VKA therapy and NOACs.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org 27.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
290 Stroke and Bleeding Risk in Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2014.44.5.281 www.e-kcj.org 59.,Non-OADS,/arxiv_data1/oa_pdf/98/79/kcj-44-281.PMC4180604.pdf
"1) Review Article http://dx.doi.org/10.4070/kcj.2014.44.5.291 Print ISSN 1738-5520 • On-line ISSN 1738-5555 How to Achieve Complete and Permanent Pulmonary   Vein Isolation without Complications Seongwook Han, MD1,2 and Chun Hwang, MD1 1Central Utah Clinic-Cardiology, Utah Valley Regional Medical Center, Provo, UT, USA   2Department of Cardiology, Dongsan Medical Center, Keimyung University, Daegu, Korea The efficacy and safety of catheter ablation for the management of atrial fibrillation (AF) has been improved in recent years.",Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Techniques used for PVI vary widely from center to center.",Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
"292 How to Achieve PVI  http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org have limitations due to the lack of real-time visualization and char - acterization of the cardiac tissue, especially in lesion formation.",Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org fossa ovale.,Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
"294 How to Achieve PVI  http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org cancer, large hiatal hernia (Fig.",Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org triggers for AF.,Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
"296 How to Achieve PVI  http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org source close to the recording system such as the RF generator, de - fibrillator or infusion pumps.",Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
"298 How to Achieve PVI  http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org Left atrium-pulmonary vein junction identification and  ablation The ideal ablation sites around the LA-PVJ should be: 1) Favorable  anatomical location for catheter manipulation to reach the target  sites with stable contact throughout the energy delivery, 2) Favor - able myocardial thickness for currently available ablation technol - ogies to achieve uniform transmural lesions but with minimum risk  of collateral damages.",Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org Acute pulmonary vein isolation confirmation and provocation  testing  Pulmonary vein isolation is confirmed with a circular catheter  once the ablation is completed.,Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
Supplementary Materials The online-only Data Supplement is available with this article at  http://dx.doi.org/10.4070/kcj.2014.44.5.291.,Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
300 How to Achieve PVI  http://dx.doi.org/10.4070/kcj.2014.44.5.291 www.e-kcj.org 6.,Non-OADS,/arxiv_data1/oa_pdf/a7/db/kcj-44-291.PMC4180605.pdf
"301 Copyright © 2014 The Korean Society of CardiologyKorean Circulation Journal Introduction With an increasing number of patients undergoing coronary an - giography and percutaneous coronary intervention (PCI), the preva -Original Article http://dx.doi.org/10.4070/kcj.2014.44.5.301 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Effect of High Dose Rosuvastatin Loading before Percutaneous   Coronary Intervention on Contrast-Induced Nephropathy Kyeong Ho Yun, MD, Jae Hong Lim, MD, Kyo Bum Hwang, MD, Sun Ho Woo, MD, Jin Woo Jeong, MD,  Yong Cheol Kim, MD, Dai-Yeol Joe, MD, Jum Suk Ko, MD, Sang Jae Rhee, MD, Eun Mi Lee, MD, and Seok Kyu Oh, MD Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Korea Background and Objectives:  Contrast-induced nephropathy (CIN) is associated with increased morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.lence of contrast-induced nephropathy (CIN) is also increasing.",Non-OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
"302 Rosuvastatin and Contrast-Induced Nephropathy http://dx.doi.org/10.4070/kcj.2014.44.5.301 www.e-kcj.org Subjects and Methods Study population We analyzed a single center, consecutive ACS and PCI cohort from  December 2009 to December 2012.",Non-OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.301 www.e-kcj.org that in the control group (18.8% vs. 13.5%, p=0.040) (Fig.",OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
"304 Rosuvastatin and Contrast-Induced Nephropathy http://dx.doi.org/10.4070/kcj.2014.44.5.301 www.e-kcj.org of rosuvastatin on preventing CIN was augmented in the subgroups  of patients with diabetes, high contrast doses, multivessel stents,  high baseline hsCRP levels, and myocardial infarction.",Non-OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.301 www.e-kcj.org in patients with diabetes and chronic kidney disease undergoing  contrast medium injection.,Non-OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
306 Rosuvastatin and Contrast-Induced Nephropathy http://dx.doi.org/10.4070/kcj.2014.44.5.301 www.e-kcj.org (PROMISS) trial--a randomized controlled study.,Non-OADS,/arxiv_data1/oa_pdf/3f/b1/kcj-44-301.PMC4180606.pdf
"307 Copyright © 2014 The Korean Society of CardiologyKorean Circulation Journal Introduction Coronary artery ectasia (CAE), an aberration of the coronary anat - omy, has been characterized as dilation of an arterial segment with  a diameter at least 1.5 times that of its adjacent normal coronary Original Article http://dx.doi.org/10.4070/kcj.2014.44.5.307 Print ISSN 1738-5520 • On-line ISSN 1738-5555 The Presence of Fragmented QRS on 12-Lead Electrocardiography  in Patients with Coronary Artery Ectasia Fatih Sen, MD, Samet Yılmaz, MD, Mevlüt Serdar Kuyumcu, MD,  Özcan Özeke, MD, Mustafa Mücahit Balcı, MD, and Sinan Aydog ˘du, MD Turkey Yuksek Ihtisas Education and Research Hospital, Cardiology Clinic, Ankara, Turkey Background and Objectives: Coronary artery ectasia (CAE) is an angiographic finding characterized by dilation of an arterial segment  with a diameter at least 1.5 times that of its adjacent normal coronary artery.",Non-OADS,/arxiv_data1/oa_pdf/ae/58/kcj-44-307.PMC4180607.pdf
"Received: April 30, 2014 Revision Received: July 15, 2014Accepted: August 4, 2014 Correspondence: Samet Yılmaz, MD, Turkey Yuksek Ihtisas Education and  Research Hospital, Cardiology Clinic, Kızılay sok No:6, Sıhhıye, Ankara 06100, TurkeyTel: 0090(507)3055883, Fax: 0090(312)3101396E-mail: sametyilmazmd@gmail.com • The authors have no financial conflicts of interest.This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.artery.1)2) Underlying etiological causes of CAE include atheroscle - rosis (50%), congenital origins (20–30%), inflammatory and con - nective tissue diseases (20–30%).3)4) CAE may result in slowed blood  flow, coronary vasospasm, dissection, and thrombus formation,  leading to increased risk of cardiac morbidity and mortality.5-7)  Fragmented QRS (fQRS) complexes are novel electrocardiograph - ic signals which reflect altered ventricular conduction around re - gions of a myocardial scar.",Non-OADS,/arxiv_data1/oa_pdf/ae/58/kcj-44-307.PMC4180607.pdf
308 Fragmented QRS in Coronary Artery Ectasia http://dx.doi.org/10.4070/kcj.2014.44.5.307 www.e-kcj.org of Q waves.,Non-OADS,/arxiv_data1/oa_pdf/ae/58/kcj-44-307.PMC4180607.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.307 www.e-kcj.org the presence of fQRS was significantly (p<0.05) higher in the CAE  group than that in the normal coronary artery group (29% vs.  6.2%, p=0.008).",Non-OADS,/arxiv_data1/oa_pdf/ae/58/kcj-44-307.PMC4180607.pdf
310 Fragmented QRS in Coronary Artery Ectasia http://dx.doi.org/10.4070/kcj.2014.44.5.307 www.e-kcj.org not statistically significant (p=0.059) (Table 4).,Non-OADS,/arxiv_data1/oa_pdf/ae/58/kcj-44-307.PMC4180607.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.307 www.e-kcj.org 2.,Non-OADS,/arxiv_data1/oa_pdf/ae/58/kcj-44-307.PMC4180607.pdf
"312 Copyright © 2014 The Korean Society of CardiologyKorean Circulation Journal Introduction Left ventricular (LV) systolic function is an independent predictor  of outcome after aortic valve replacement (AVR) in patients with  severe aortic stenosis (AS).1)2) Previous studies have mostly shown  that patients with a reduced ejection fraction (EF) and severe AS have Original Article http://dx.doi.org/10.4070/kcj.2014.44.5.312 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Late Gadolinium Enhancement in Cardiac MRI in Patients   with Severe Aortic Stenosis and Preserved Left Ventricular Systolic Function Is Related to Attenuated Improvement of Left Ventricular Geometry and Filling Pressure after Aortic Valve Replacement Junbeom Park, MD1, Hyuk-Jae Chang, MD1,2, Jung-Ho Choi, MD1, Pil-Sung Yang, MD1,   Sang-Eun Lee, MD1, Ran Heo, MD1, Sanghoon Shin, MD1, In-Jeong Cho, MD1, Young-Jin Kim, MD1,   Chi Young Shim, MD1, Geu-Ru Hong, MD1, and Namsik Chung, MD1 1Division of Cardiology and Radiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul,   2Severance Biomedical Science Institute, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea Background and Objectives:  We investigated echocardiographic predictors: left ventricular (LV) geometric changes following aortic  valve replacement (AVR) according to the late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) in patients  with severe aortic stenosis (AS) and preserved LV systolic function.Subjects and Methods: We analyzed 41 patients (24 males, 63.1 ±8.7 years) with preserved LV systolic function who were scheduled to  undergo AVR for severe AS.",Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/  by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.higher operative mortality and poor survival benefit versus those  with normal EF.3-6) However, patients with reduced EF represent <5%  of the population of patients with AS,2)4) and most patients who un - derwent AVR have preserved LV systolic function.",Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org method is in patients with preserved EF and severe AS.,Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
"314 Severe Aortic Stenosis and Late Gadolinium Enhancement http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org was performed on a 1.5 T cardiac magnetic resonance system (Achie - va 1.5 T; Philips Medical Systems 5680 DA, the Netherlands).",Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org Table 1.,OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
316 Severe Aortic Stenosis and Late Gadolinium Enhancement http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org patients.,Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org important role in predicting the long-term outcome and improve - ment of LV remodeling after AVR.,Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
318 Severe Aortic Stenosis and Late Gadolinium Enhancement http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org the enrollment of additional patients.,Non-OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org based on the bandwidth of the ultrasound Doppler signal with appli - cations in blood/tissue segmentation in the left ventricle.,OADS,/arxiv_data1/oa_pdf/b2/66/kcj-44-312.PMC4180608.pdf
"320 Copyright © 2014 The Korean Society of CardiologyKorean Circulation Journal Introduction Milrinone, a phosphodiesterase III inhibitor currently used to treat Original Article http://dx.doi.org/10.4070/kcj.2014.44.5.320 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Safety and Efficacy of the Off-Label Use of Milrinone   in Pediatric Patients with Heart Diseases Joowon Lee, MD1, Gi Beom Kim, MD1, Hye Won Kwon, MD1, Bo Sang Kwon, MD1, Eun Jung Bae, MD1,   Chung Il Noh, MD1, Hong Gook Lim, MD2, Woong Han Kim, MD2, Jeong Ryul Lee, MD2, and Yong Jin Kim, MD2 1Departments of Pediatrics and 2Thoracic and Cardiovascular Surgery, Seoul National University Children’s Hospital, Seoul, Korea Background and Objectives: Milrinone is often used in children to treat acute heart failure and prevent low cardiac output syndrome af - ter cardiac surgery.",Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pediatric patients with cardiac diseases, increases the level of cyclic  adenosine monophosphate in the myocardium and vascular smooth muscle.",Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org to improve heart contractility in patients with septic shock.7)  Milrinone is currently one of the most commonly used off-label  cardiovascular medications in children.8) Although a few reports  showed the efficacy and safety of short-term milrinone treatment  (for about 35 hours) in children with heart disease,9)10) the safety and  efficacy of long-term use of milrinone in children is limited due to  a lack of sufficient evidence-based studies in pediatric populations.",Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
322 Milrinone Use in Children with Heart Disease http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org Statistical analysis Changes in hemodynamic parameters and echocardiographic  data were analyzed using a pairwise comparison test and the Wil - coxon signed-rank test.,Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org Safety There were no reports of adverse events in the majority of ad - missions (78.7%) (Table 5).,Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
"324 Milrinone Use in Children with Heart Disease http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org infusion rate, and duration of milrinone treatment were not associ - ated with thrombocytopenia.",Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org reduction in milrinone infusion rate.,Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
326 Milrinone Use in Children with Heart Disease http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org long-term support with milrinone was safe and effective in infants  with cardiomyopathy awaiting heart transplantation.,Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.320 www.e-kcj.org diol 2014;113:535-40.,Non-OADS,/arxiv_data1/oa_pdf/e0/d8/kcj-44-320.PMC4180609.pdf
"328 Copyright © 2014 The Korean Society of CardiologyKorean Circulation Journal Introduction Kawasaki disease (KD) is an acute systemic vasculitis that occurs Original Article http://dx.doi.org/10.4070/kcj.2014.44.5.328 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Clinically Useful Predictors of Resistance to Intravenous   Immunoglobulin and Prognosis of Coronary Artery Lesions   in Patients with Incomplete Kawasaki Disease Kee Hyun Cho, MD and Soo Jung Kang, MD Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, Korea Background and Objectives: The prevalence of incomplete Kawasaki disease (iKD) is progressively increasing.",Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.in young children.",Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org can lead to increased prevalence of coronary artery lesions (CALs)  in patients with KD,4)9) resistance to IVIG may be a risk factor for  the development of CALs.",Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
330 Predicts Resistance to Treatment and Prognosis in Incomplete Kawasaki Disease http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org the Mann-Whitney U test for continuous variables and the chi- square test for categorical variables.,Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org um levels in addition to higher SEG% and TB compared to the IVIG  responders.,Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
"332 Predicts Resistance to Treatment and Prognosis in Incomplete Kawasaki Disease http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org and after IVIG treatment showed that CRP and NT-pro BNP levels  were found to be significantly elevated after IVIG treatment in IVIG  non-responders of the iKD group, whereas ESR was found to be  significantly elevated in IVIG non-responders of the cKD group  (Table 5).",OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org resistance in patients with cKD who remained febrile on the 6th  day of IVIG treatment have been studied by Fukunishi et al.15) with  the exclusion of patients with iKD.,Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
334 Predicts Resistance to Treatment and Prognosis in Incomplete Kawasaki Disease http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org of prednisolone in addition to IVIG in IVIG non-responders.,Non-OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.328 www.e-kcj.org cells and NK1.1 Ag+ T cells in T helper 1 immune responses.,OADS,/arxiv_data1/oa_pdf/3a/61/kcj-44-328.PMC4180610.pdf
"LVH is an important predictor of mortality and morbidity indepen-dent of other major cardiac risk factors, both in the general popu -Original Article http://dx.doi.org/10.4070/kcj.2014.44.5.336 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Bilirubin Level is Associated with Left Ventricular  Hypertrophy Independent of Blood Pressure  in Previously Untreated Hypertensive Patients Teslime Ayaz, MD1, Murtaza Emre Durakog ˘lugil, MD2, Sinan Altan Kocaman, MD2,   Tug˘ba Durakog ˘lugil, MD3, Turan Erdog ˘an, MD2, Osman Zikrullah S ¸ahin, MD1,   Serap Baydur S ¸ahin, MD1, Yüksel C ¸ic¸ek, MD2, and Ömer S ¸atirog˘lu, MD2 1Departments of Internal Medicine, 2Cardiology, and 3Radiology, Recep Tayyip Erdog ˘an University, Education and Research Hospital, Rize, Turkey Background and Objectives: Left ventricular hypertrophy (LVH), a sign of subclinical cardiovascular disease, is an important predictor of  cardiovascular morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
"Received: April 20, 2014 Revision Received: July 5, 2014Accepted: August 19, 2014 Correspondence: Murtaza Emre Durakog ˘lugil, MD, Recep Tayyip Erdo g˘an  University, School of Medicine, Department of Cardiology, Islampasa Mah., Rize 53100, TurkeyTel: 90 (464) 212 30 09, Fax: 90 (464) 212 30 15E-mail: emredur@hotmail.com • The authors have no financial conflicts of interest.This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.lation and in patients with HT.1) Moreover, LVH is generally accepted  as a marker of subclinical cardiovascular disease.2) Regression of  LVH is associated with lower cardiovascular mortality, independent  of blood pressure (BP) reduction.3)  Left ventricular hypertrophy is related to various clinical and an - thropologic parameters.",Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org of free radicals.,Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
"338 Bilirubin and LV Hypertrophy http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org Measurement of carotid intima-media thickness Ultrasonography was performed on all patients using a high-res - olution ultrasonography scanner (Xario, Toshiba Medical Systems,  Tokyo, Japan) with a PLT-805AT linear array transducer.",OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org Left ventricular mass and study parameters Left ventricular mass values did not differ within subgroups form- ed by the presence versus absence of the categorical variables, in -cluding diabetes mellitus (224 ±63 g vs. 216 ±51 g, p=0.627), smok - ing status (237 ±86 g vs. 213 ±40 g, p=0.064), hyperlipidemia (198 ±  49 g vs. 222 ±53 g, p=0.060), and family history of CAD (213 ±48 g  vs. 234 ±65 g, p=0.171).",Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
340 Bilirubin and LV Hypertrophy http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org drome.21) Studies investigating the effect of SUA on LVH revealed  conflicting results.,Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org covalently bound albumin and bilirubin.,Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
342 Bilirubin and LV Hypertrophy http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org different than under in vitro  conditions or that the bilirubin levels  may reflect another process that has not yet been elucidated.,Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.336 www.e-kcj.org 26.,Non-OADS,/arxiv_data1/oa_pdf/e3/25/kcj-44-336.PMC4180611.pdf
"However, concerns still exist over treating patients who have previously undergone mitral valve sur-gery due to the proximity and the potential mechanical interference Case Report http://dx.doi.org/10.4070/kcj.2014.44.5.344 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Transcatheter Aortic Valve Implantation in a Patient   with Previous Mitral Valve Replacement Sung Woo Moon, MD1, Young-Guk Ko, MD1, Geu-Ru Hong, MD1, Sak Lee, MD2, Byung-Chul Chang, MD2,   Jae-Kwang Shim, MD3, Young-Ran Kwak, MD3, and Myeong-Ki Hong, MD1 1Division of Cardiology, 2Departments of Thoracic and Cardiovascular Surgery, and 3Anesthesiology and Pain Medicine, Severance Cardiovascular Hospital,   Yonsei University College of Medicine, Seoul, Korea Transcatheter aortic valve implantation (TAVI) has shown favorable outcomes in patients with severe symptomatic aortic valve stenosis  who are at high surgical risk or are unsuitable candidates for open heart surgery.",Non-OADS,/arxiv_data1/oa_pdf/ad/6b/kcj-44-344.PMC4180612.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.between the TAVI device and the previously implanted mitral pros - thesis.",Non-OADS,/arxiv_data1/oa_pdf/ad/6b/kcj-44-344.PMC4180612.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.344 www.e-kcj.org right ventricular systolic pressure of 47 mm Hg and mild tricuspidal  regurgitation.,Non-OADS,/arxiv_data1/oa_pdf/ad/6b/kcj-44-344.PMC4180612.pdf
"346 TAVI in Patient with Previous MVR http://dx.doi.org/10.4070/kcj.2014.44.5.344 www.e-kcj.org using a 22 mm balloon (Maxi LDTM, Cordis Corporation, Johnson &  Johnson Ltd., Bridgewater, NJ, USA) was performed under rapid pac - ing.",Non-OADS,/arxiv_data1/oa_pdf/ad/6b/kcj-44-344.PMC4180612.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.344 www.e-kcj.org The technical concerns regarding TAVI in patients with prosthetic  mitral valves are due to the potential interactions between the aortic  and mitral prostheses at the anatomic aorto-mitral continuity.,Non-OADS,/arxiv_data1/oa_pdf/ad/6b/kcj-44-344.PMC4180612.pdf
"Case The patient is a 39-year-old veterinarian who developed slowly  progressive muscle weakness and wasting of the shoulder girdle mus-Case Report http://dx.doi.org/10.4070/kcj.2014.44.5.348 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Intermittent Pre-Excitation-Syndrome  in Facio-Scapulo-Humeral Muscular Dystrophy Josef Finsterer, MD1, Claudia Stöllberger, MD2, Edmund Gatterer, MD2, and Sibylle Jakubiczka, PhD3 1Krankenanstalt Rudolfstiftung, Vienna, 2Second Medical Department, Krankenanstalt Rudolfstiftung, Vienna, Austria   3Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany Pre-excitation-syndrome has not been reported as a phenotypic feature of facio-scapulo-humeral muscular dystrophy (FSH-MD).",Non-OADS,/arxiv_data1/oa_pdf/cc/04/kcj-44-348.PMC4180613.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.348 www.e-kcj.org electrocardiography (Fig.,Non-OADS,/arxiv_data1/oa_pdf/cc/04/kcj-44-348.PMC4180613.pdf
"350 Intermittent Pre-Excitation-Syndrome in Facio-Scapulo-Humeral Muscular Dystrophy http://dx.doi.org/10.4070/kcj.2014.44.5.348 www.e-kcj.org Accordingly, echocardiography in FSH-MD may show enlarged right  cardiac cavities or restricted right ventricular movement, attributed  to thoracic deformities2)8) or hypertrophic cardiomyopathy.4)10) Ad- ditionally, myocardial scintigraphy revealed reduced Thallium-201  uptake due to suspected myocardial fibrosis.7)  This case shows that there is indeed cardiac involvement in FSH- MD, manifesting either as hypertrophic cardiomyopathy or arrhy- thmias.",Non-OADS,/arxiv_data1/oa_pdf/cc/04/kcj-44-348.PMC4180613.pdf
"Case Report http://dx.doi.org/10.4070/kcj.2014.44.5.351 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Successful Stent Implantation for Aortoiliac Bifurcation Stenosis   in a Young Patient with Behçet’s Disease Suyoung Jang, MD, Myung Ho Jeong, MD, Hyung Ki Jung, MD, Kyung Jin Lee, MD,  Kye Hun Kim, MD, Young Joon Hong, MD, Ju Han Kim, MD, and Youngkeun Ahn, MD  Department of Cardiovascular Medicine, Chonnam National University Medical School, Gwangju, Korea Behçet’s disease (BD) is a multisystem vascular inflammatory disease.",Non-OADS,/arxiv_data1/oa_pdf/d2/c7/kcj-44-351.PMC4180614.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.The pain was rated 6–7 on a scale of 1 to 10.",Non-OADS,/arxiv_data1/oa_pdf/d2/c7/kcj-44-351.PMC4180614.pdf
"352 Stenting for Aortoiliac Bifurcation Stenosis in Behçet’s Disease http://dx.doi.org/10.4070/kcj.2014.44.5.351 www.e-kcj.org angioplasty for aortoiliac bifurcation was performed with two  7×20 mm Synergy balloons (Boston Scientific, Natick, MA, USA)  (Fig.",Non-OADS,/arxiv_data1/oa_pdf/d2/c7/kcj-44-351.PMC4180614.pdf
"http://dx.doi.org/10.4070/kcj.2014.44.5.351 www.e-kcj.org autoimmune disease that results from damage to blood vessels  throughout the body, although the etiology of BD remains uncer - tain.",Non-OADS,/arxiv_data1/oa_pdf/d2/c7/kcj-44-351.PMC4180614.pdf
354 Stenting for Aortoiliac Bifurcation Stenosis in Behçet’s Disease http://dx.doi.org/10.4070/kcj.2014.44.5.351 www.e-kcj.org disease.,Non-OADS,/arxiv_data1/oa_pdf/d2/c7/kcj-44-351.PMC4180614.pdf
"2) Here, we report the case of a pa - tient with a prasugrel induced skin rash that was resolved after sub - stitution of prasugrel to clopidogrel.Case Report http://dx.doi.org/10.4070/kcj.2014.44.5.355 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Prasugrel-Induced Hypersensitivity Skin Reaction Soo-Han Kim, MD, Sang-Don Park, MD, Yong-Soo Baek, MD, Seon-Young Lee, MD,  Sung-Hee Shin, MD, Sung-Il Woo, MD, Dae-Hyeok Kim, MD, and Jun Kwan, MD Division of Cardiology, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea We report a case of hypersensitivity skin reaction to prasugrel.",Non-OADS,/arxiv_data1/oa_pdf/cb/f3/kcj-44-355.PMC4180615.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Case A 41-year-old male visited the EMC of our hospital complaining  of a sharpening chest pain of his mid sternum lasting for 1 hour.",Non-OADS,/arxiv_data1/oa_pdf/cb/f3/kcj-44-355.PMC4180615.pdf
"356 Prasugrel-Induced Hypersensitivity Skin Reaction http://dx.doi.org/10.4070/kcj.2014.44.5.355 www.e-kcj.org furosemide, spironolactone and prasugrel; however, he revisited our  outpatient clinic after 5 days complaining of a worsened whole  body skin rash with pruritic symptoms (Fig.",Non-OADS,/arxiv_data1/oa_pdf/cb/f3/kcj-44-355.PMC4180615.pdf
http://dx.doi.org/10.4070/kcj.2014.44.5.355 www.e-kcj.org Mutnick7) reported the first case of successful desensitization to  prasugrel using a 7-hour desensitization protocol.,OADS,/arxiv_data1/oa_pdf/cb/f3/kcj-44-355.PMC4180615.pdf
"3) The electrocardiogram (ECG) included in this case report is  not of much help to ascertain the onset of TTS (ST-segment eleva - tion and attenuation of the voltage of the QRS complexes, early in the illness, 4)5) with deep T-wave inversions with QTc prolongation in Letter to the Editor http://dx.doi.org/10.4070/kcj.2014.44.5.358 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Inverse Takotsubo Syndrome Resulting from a Fall, Malleolar Fracture,   Anesthesia, Surgery, or Complicating Pulmonary Embolism?",Non-OADS,/arxiv_data1/oa_pdf/34/5e/kcj-44-358.PMC4180616.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.subsequent evolution.",Non-OADS,/arxiv_data1/oa_pdf/34/5e/kcj-44-358.PMC4180616.pdf
Statistical analysis of tumor take was performed using the ELDA Web-based tool (http://bioinf.wehi.edu.au/software/elda/).74 Statistical analysis Data are presented as mean ± s.e.m.,OADS,/arxiv_data1/oa_pdf/27/30/onc201471a.PMC4180644.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)SOX2 regulates melanoma-initiating cells R Santini et al 4708 Oncogene (2014) 4697 –4708 © 2014 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/27/30/onc201471a.PMC4180644.pdf
ICH Expert Working Group International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf (accessed 19 February 2013).,Non-OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
"SACHRP Letter to the Secretary: FAQs, Terms and Recommendations on Informed Consent and Research Use of Biospecimens; http://www.hhs.gov/ohrp/sachrp/20110124 attachmentatosecletter.html (accessed 19 February 2013).",Non-OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
Clinical Laboratory Improvement Amendments (CLIA); http://www.cms.gov/Regulations-and-Guidance/ Legislation/CLIA/index.html?redirect 5/CLIA (accessed 19 February 2013).,Non-OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
Device Advice: Comprehensive Regulatory Assistance; http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ default.htm.,Non-OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
Investigational New Drug (IND) Application; http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandAppr oved/ApprovalApplications/ InvestigationalNewDrugINDApplication/ default.htm (accessed 19 February 2013).,OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
Draft Guidance for Industry and FDA Staff: Medical Devices: the Pre-submission Program and Meetings with FDA Staff (US Department of Health & Human Services); http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ ucm310375.htm (accessed 19 February 2013).,Non-OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
"To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-sa/3.0RESEARCH PERSPECTIVE 320 | NATURE | VOL 502 | 17 OCTOBER 2013 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/22/58/41586_2013_Article_BFnature12564.PMC4180668.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/61/62/srep06513.PMC4180805.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6513 | DOI: 10.1038/srep06513 8",Non-OADS,/arxiv_data1/oa_pdf/61/62/srep06513.PMC4180805.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/53/6b/srep06518.PMC4180808.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6518 | DOI: 10.1038/srep06518 8",Non-OADS,/arxiv_data1/oa_pdf/53/6b/srep06518.PMC4180808.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/83/d6/srep06514.PMC4180809.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6514 | DOI: 10.1038/srep06514 7",Non-OADS,/arxiv_data1/oa_pdf/83/d6/srep06514.PMC4180809.pdf
http://www.ebi.ac.uk/msd-srv/ssm/ (Date of access: 01/ 06/2002).,Non-OADS,/arxiv_data1/oa_pdf/74/ba/srep06214.PMC4180811.pdf
All authors reviewed the manuscript.Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/74/ba/srep06214.PMC4180811.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/45/9c/srep06509.PMC4180821.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/3e/90/srep06492.PMC4180822.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6492 | DOI: 10.1038/srep06492 7",Non-OADS,/arxiv_data1/oa_pdf/3e/90/srep06492.PMC4180822.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6468 | DOI: 10.1038/srep06468 9",Non-OADS,/arxiv_data1/oa_pdf/68/76/srep06468.PMC4180823.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/f4/4d/srep06484.PMC4180825.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/04/3a/srep06487.PMC4180826.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6487 | DOI: 10.1038/srep06487 7",Non-OADS,/arxiv_data1/oa_pdf/04/3a/srep06487.PMC4180826.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/48/8a/srep06480.PMC4180827.pdf
2014. http://www.ema.europa.eu/ema/index.,Non-OADS,/arxiv_data1/oa_pdf/00/28/40265_2014_Article_278.PMC4180907.pdf
2014. http://www.xareltohcp.com/sites/default/ﬁles/ pdf/xarelto_0.pdf#zoom=100 .,Non-OADS,/arxiv_data1/oa_pdf/00/28/40265_2014_Article_278.PMC4180907.pdf
2014. http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/002148/human_ med_001449.jsp&mid=WC0b01ac058001d124 .,Non-OADS,/arxiv_data1/oa_pdf/00/28/40265_2014_Article_278.PMC4180907.pdf
2014. http://packageinserts.bms.com/pi/ pi_eliquis.pdf .,Non-OADS,/arxiv_data1/oa_pdf/00/28/40265_2014_Article_278.PMC4180907.pdf
http://www.nejm.org/doi/suppl/10.1056/ NEJMoa1007903/suppl_ﬁle/nejmoa1007903_protocol.pdf .,OADS,/arxiv_data1/oa_pdf/00/28/40265_2014_Article_278.PMC4180907.pdf
Organ Procurement and Transplant Network (OPTN) Annual Report 2011. http://srtr.transplant.hrsa.gov/annual_reports/2011/ default.aspx .,OADS,/arxiv_data1/oa_pdf/b2/84/40265_2014_Article_277.PMC4180909.pdf
http://eur-lex.europa.eu/Lex-UriServ/LexUriServ.do?uri=CELEX:31992L0043:EN:NOT.,Non-OADS,/arxiv_data1/oa_pdf/f0/60/eff0023-0498.PMC4180929.pdf
http://eur-lex.europa.eu/LexUri Serv/LexUriServ.do?uri=CELEX:32000L0060:EN:NOT.,Non-OADS,/arxiv_data1/oa_pdf/f0/60/eff0023-0498.PMC4180929.pdf
http://www.epw.senate.gov/water.pdf (version amended in 2002).,Non-OADS,/arxiv_data1/oa_pdf/f0/60/eff0023-0498.PMC4180929.pdf
[Keywords : RNA polymerase II; TRF2; TBP; evolution; bilateria; regulatory systems] Corresponding author: jkadonaga@ucsd.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.250563.114.,Non-OADS,/arxiv_data1/oa_pdf/99/fb/2071.PMC4180970.pdf
Budding yeast telomerase similarly relies on two regu- latory subunits: Est1 and Est3 (Lundblad and Szostak /C2112014 Tucey and Lundblad This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.,Non-OADS,/arxiv_data1/oa_pdf/b3/52/2077.PMC4180971.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.3Present address: Department of Microbiology, Monash University, Melbourne 3000, VIC, Australia Corresponding author: lundblad@salk.edu Article published online ahead of print.",Non-OADS,/arxiv_data1/oa_pdf/b3/52/2077.PMC4180971.pdf
Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.246256.114.,Non-OADS,/arxiv_data1/oa_pdf/b3/52/2077.PMC4180971.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
Article and publication date are online at http://www.genesdev.or g/cgi/doi/10.1101/gad.248567.114.,Non-OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
Materials and methods Patients Patient NCI-275-1 and his family were participants in an in- stitutional review board (IRB)-approved longitudinal cohort study at the National Cancer Institute (NCI) entitled ‘‘EtiologicInvestigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes’’ (NCI 02-C-0052; http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"novocraft.com), Picard software version 1.67 (http://picard.sourceforge.net), and the Genome Analysis Toolkit (GATK)(http://www.broadinstitute.org/gatk) (DePristo et al.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
2013) using data from the University of California atSanta Cruz (UCSC) GoldenPath database (http://hgdownload.cse.,OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"ucsc.edu/goldenPath/hg19/database), the ESP6500 data set from the Exome Variant Server, NHLBI ESP (http://evs.gs.washington.edu/EVS; accessed August 2012), the Institute of Systems BiologyKAVIAR (known variants) database (http://db.systemsbiology.net/ kaviar; Glusman et al.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"2001) build 137 (http://www.ncbi.nlm.nih.gov/projects/SNP), and the 1000Genomes Project (http://www.1000genomes.org; Abecasis et al.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
In silico analysis PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2; Adzhubei et al.,OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"2010), SIFT (http://sift.jcvi.org; Kumar et al.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"2009), PROVEAN (http://provean.jcvi.org; Choi et al.",Non-OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"2012), MutationAssessor (http://mutationassessor.org; Reva et al.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"2011), MutationTaster(http://mutationtaster.org; Schwarz et al.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"2010), FATHMM(http://fathmm.biocompute.org.uk; Shihab et al.",Non-OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
Multiple sequence alignments were generated forhomologous TPP1 protein sequences using COBALT (http:// www.st-va.ncbi.nlm.nih.gov/tools/cobalt; Papadopoulos and Agarwala 2007) and viewed in Jalview (http://www.jalview.org;Waterhouse et al.,OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
"The homology model was subjected to energy minimization using the crystallography and NMR (nuclear magnetic resonance) system (CNS) program(http://cns-online.org/v1.3; Brunger 2007) to furnish the modeldisplayed in Figure 6, B and C. Acknowledgments We thank Valerie Tesmer (J.N.",OADS,/arxiv_data1/oa_pdf/ec/0e/2090.PMC4180972.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/f9/46/2103.PMC4180973.pdf
Article and publication date are online at http://www.genesdev.org/ cgi/doi/10.1101/gad.248005.114.,Non-OADS,/arxiv_data1/oa_pdf/f9/46/2103.PMC4180973.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.,Non-OADS,/arxiv_data1/oa_pdf/30/0a/2120.PMC4180974.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.4Present address: Department of Bioengineering, University of California at San Diego, La Jolla, CA 92093, USA.",Non-OADS,/arxiv_data1/oa_pdf/30/0a/2120.PMC4180974.pdf
Corresponding author: ahoffmann@ucla.edu Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.244749.114.,Non-OADS,/arxiv_data1/oa_pdf/30/0a/2120.PMC4180974.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/0d/da/2134.PMC4180975.pdf
"Af- ter six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding author: joycej@mskcc.org Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.249599.114.",Non-OADS,/arxiv_data1/oa_pdf/0d/da/2134.PMC4180975.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/27/a5/2151.PMC4180976.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http:// creativecommons.org/licenses/by-nc/4.0/.Corresponding authors: miguel.beato@crg.es, mmarti@pcb.ub.cat Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.241422.114.",Non-OADS,/arxiv_data1/oa_pdf/27/a5/2151.PMC4180976.pdf
"To trans- form such data into a 3D conformation of higher-order chromatin folding, we used the IMP (http://www.integrativemodeling.org;Russel et al.",OADS,/arxiv_data1/oa_pdf/27/a5/2151.PMC4180976.pdf
"Data access Data sets used in this study can be accessed at Gene Expression Omnibus (accession, GSE53463; http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?token =kdgbgoucpzurtyh &acc=GSE53463).",OADS,/arxiv_data1/oa_pdf/27/a5/2151.PMC4180976.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/37/ce/2163.PMC4180977.pdf
Article and publication date are online at http://www.genesdev.org/ cgi/doi/10.1101/gad.245670.114.,Non-OADS,/arxiv_data1/oa_pdf/37/ce/2163.PMC4180977.pdf
"Taken together, these results show that short TRF2 preferentially activates the ftzandgtDPE- dependent promoters, whereas the long TRF2 activates theDPE-dependent as well as the TATA-dependent ftzandgt promoters.Depletion of endogenous TRF2 reduces DPE-dependent but not TATA-dependent transcription Drosophila S2R +cells express moderately high levels of TRF2 (FlyBase, http://www.flybase.org).",Non-OADS,/arxiv_data1/oa_pdf/37/ce/2163.PMC4180977.pdf
Generation of dsRNA probes Four dsRNA probes directed against TRF2 were chosen based on http://www.dkfz.de/signaling/e-rnai3.,OADS,/arxiv_data1/oa_pdf/37/ce/2163.PMC4180977.pdf
"Using the FlyBase converter tool (http://www.flybase.org), we identified all of the transcripts that contain an induced microarray probe and initiate at different chromo- somal positions.",OADS,/arxiv_data1/oa_pdf/37/ce/2163.PMC4180977.pdf
"To visually illustrate the elements, we calculated a position-specific frequency matrix for each set anddrew them using http://demo.tinyray.com/weblogo.",OADS,/arxiv_data1/oa_pdf/37/ce/2163.PMC4180977.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/b1/bd/2175.PMC4180978.pdf
Corresponding author: guillermo.oliver@stjude.org Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.216226.113.,Non-OADS,/arxiv_data1/oa_pdf/b1/bd/2175.PMC4180978.pdf
"7 Two, live-attenuated, orally administered RV  vaccines are currently licensed and available for use in several  *Correspondence to: Rong-cheng Li; Email: lrch2001@163.com Submitted: 07/01/2013; Revised: 07/31/2013; Accepted: 08/29/2013http://dx.doi.org/10.4161/hv.26319Human rotavirus vaccine (RIX4414) efficacy   in the first two years of life A randomized, placebo-controlled trial in China Rong-cheng Li1,*, Teng h uang1, Yanping Li1, Dong Luo2, Junhui Tao3, Botao Fu4, Guoai s i5, Yi Nong1, Zhaojun Mo1,   XueYan Liao6, Ivy Luan6, haiwen Tang6, Niraj Rathi7, Naveen Karkada7, and h tay h tay h an8 1GuangXi c enter for Disease Prevention and c ontrol; Guangxi, autonomous Region PR c hina; 2Liucheng c ounty c enter for Disease Prevention and c ontrol;   Guangxi, autonomous Region PR c hina; 3Liujiang c ounty c enter for Disease Prevention and c ontrol; Guangxi, autonomous Region PR c hina;   4Luzhai county c enter for Disease Prevention and c ontrol; Guangxi, autonomous Region PR c hina; 5Jinchengjiang region c enter for Disease Prevention and c ontrol; Guangxi,  autonomous Region PR c hina; 6Glaxos mithKline Vaccines; Beijing, PR c hina; 7Glaxo smithKline Pharmaceuticals Ltd.; Bangalore, India; 8Glaxo smithKline Vaccines; Philadelphia,  Pa Usa Keywords:  rotavirus gastroenteritis, efficacy, RIX4414, China, safety, Guangxi Province Abbreviations:  ATP, according-to-protocol; CCID50, median cell culture infectious dose; CI, confidence interval; ELISA,  enzyme-linked immunosorbent assay; EPI, expanded program on immunization; GE, gastroenteritis; LLR, Lanzhou lamb  rotavirus; RV, rotavirus; SAE, serious adverse event; SAS, statistical analysis system; SD, standard deviation; VE, vaccine efficacy Rotaviruses (RV) are a major cause of severe gastroenteritis (G e) in children aged <5 y.",Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Pediatr Infect Dis  J 2009; 28(Suppl):S50-3; http://dx.doi.org/10.1097/ INF.0b013e3181967bee ; PMID:19252423 2.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Expert Rev Vaccines 2009 ;  8:1627 -41; http://dx.doi.org/10.1586/erv.09.136 ;  PMID:19943758 4.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
J Infect Dis 2009 ; 200(Suppl  1):S9-15; http://dx.doi.org/10.1086/605025 ;  PMID:19817620 6.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine   2012 ; 30:6940 -5; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine  2008 ; 26:3192 -6;  http://dx.doi.org/10.1016/j.vaccine.2008.03.073 ;  PMID:18485546 9.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
J Infect  Dis 2009 ; 200(Suppl 1 ):S167 - 73; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
N Engl J Med 2006 ; 354:11- 22; http://dx.doi.org/10.1056/NEJMoa052434 ;  PMID:16394298 12.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
N Engl J Med 2006 ; 354:23- 33; http://dx.doi.org/10.1056/NEJMoa052664 ;  PMID:16394299 13.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Lancet  2007 ;  370:1757 -63; http://dx.doi.org/10.1016/S0140- 6736(07)61744-9 ; PMID:18037080 14.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine  2012 ;  30(Suppl 1 ):A44-51; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine  2012 ;  30(Suppl 1 ):A36-43; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine   2009 ; 27:5936 -41; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine  2012 ; 30S:A114 -21; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine  2012 ; 31:154-8; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Clin Infect Dis 2009 ; 49:1202 -10; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Arch Virol   2012 ; 157:881-7; http://dx.doi.org/10.1007/s00705- 012-1235-9 ; PMID:22318672 23.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
J Clin  Virol  2011 ; 50:84-7; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine   2011 ; 29:6335 -41; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Pediatr Infect  Dis J 2009 ; 28:261-6; http://dx.doi.org/10.1097/ INF.0b013e3181907177 ; PMID:19289978 26.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Pediatr Infect Dis J 2009 ; 28:225-32;  http://dx.doi.org/10.1097/INF.0b013e31819715fa ;  PMID:19209095 27.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Vaccine  2011 ; 29:3061 -6; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Pediatr Infect  Dis J 2012 ; 31:736-44; http://dx.doi.org/10.1097/ INF.0b013e318253add3 ; PMID:22695189 29.,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
Scand J Infect Dis 1990 ; 22:259- 67; http://dx.doi.org/10.3109/00365549009027046 ;  PMID :2371542,OADS,/arxiv_data1/oa_pdf/42/b5/hvi-10-11.PMC4181005.pdf
"The 95% CI for the RR was based on the exact conditional likelihood approach  *Correspondence to: Hubert Buyse; Email: hubert.x.buyse@gsk.com Submitted: 07/05/2013; Revised: 08/29/2013; Accepted: 09/13/2013http://dx.doi.org/10.4161/hv.26476The human rotavirus vaccine Rotarix™ in infants An integrated analysis of safety and reactogenicity hubert Buyse1,*, Carlota Vinals1, Naveen Karkada2, and h tay h tay h an3 1GlaxoSmithKline Vaccines; Wavre, Belgium; 2GlaxoSmithKline Vaccines; Bangalore, India; 3GlaxoSmithKline Vaccines; King of p russia, p A USA Keywords:  rotavirus gastroenteritis, human rotavirus vaccine, Rotarix™, vaccine safety, intussusceptions, reactogenicity Abbreviations:  AE, adverse event; CI, confidence interval; DBRCT, double-blind, randomized, placebo-controlled trial; RR,  relative risk; RV, rotavirus; RVGE, rotavirus gastroenteritis; SAE, serious adverse event; SD, standard deviation An integrated analysis of safety and reactogenicity data was undertaken for 28 randomized, placebo-controlled, double- blind p hase II and III trials (DB rCts) of the oral live-attenuated human rotavirus vaccine, r otarix™ (GlaxoSmithKline Vaccines).",Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Emerg Infect Dis  2003; 9:565-72;  PMID:12737740 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
J Infect Dis 2009;  200(Suppl 1):S9-15;  PMID:19817620 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Paediatr Drugs  2010; 12:235-56;  PMID:20593908 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Lancet 2007; 370:1757-63; PMID:18037080 ; http://dx.doi.org/10.1016/ S0140-6736(07)61744-9 7.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Vaccine 2012; 30:4552- 7; PMID:22497874 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
N Engl J Med  2010; 362:289-98;  PMID:20107214 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Vaccine 2011; 29:6335- 41; PMID:21640780 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
"Information pertaining to labeling revision for RotaTeq, June 15, 2007. http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm142393.htm .",Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Pediatr Infect Dis J 2009; 28:225- 32; PMID:19209095 ; http://dx.doi.org/10.1097/ INF.0b013e31819715fa 15.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Pediatr Infect Dis J 2010; 29:673-5; PMID:20300045 ; http://dx.doi.org/10.1097/ INF.0b013e3181da8f2316.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
N Engl J Med 2010; 362:299- 305; PMID:20107215 ; http://dx.doi.org/10.1056/ NEJMoa0905211 17.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Int J Infect Dis 2011; 15:e206- 10; PMID:21193339 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
J Paediatr Child Health 2011;  47:266-70;  PMID:21244557 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Pediatr Infect Dis J 2011; 30:e120- 5; PMID:21436757 ; http://dx.doi.org/10.1097/ INF.0b013e318214b811 20.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
N Engl J Med 2011; 365:772-3; PMID:21864191 ;  http://dx.doi.org/10.1056/NEJMc1100062 20.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Int J Infect Dis 2012; 16:e94- 8; PMID:22154592 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Pediatr Infect Dis J  2012; 31:736-44;  PMID:22695189 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
N Engl J Med 2011; 364:2283- 92; PMID:21675888 ; http://dx.doi.org/10.1056/ NEJMoa101295226.,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Clin Infect Dis 2012; 54:1397-405;  PMID:22431803 ; http://dx.doi.org/10.1093/cid/ cis191 28.,Non-OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
Pediatr Infect Dis J 2013;  32:1-7;  PMID:22929172 ; http://dx.doi.org/10.1097/ INF.0b013e318270362c,OADS,/arxiv_data1/oa_pdf/37/6f/hvi-10-19.PMC4181014.pdf
"During the same period, there was a 12% reduction  Correspondence to: David S Fedson; Email: dfedson@wanadoo.fr Submitted: 08/23/2013; Accepted: 09/09/2013http://dx.doi.org/10.4161/hv.26422Response to: Hollingsworth R, Isturiz R. Pneumococcal vaccination of older adults: Conjugate or polysaccharide?",Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Hum Vaccin & Immunother 2014; 10: 45-6  (Forthcoming); PMID: 24018552; http://dx.doi.org/10.4161/hv.26330Pneumococcal conjugate vaccination   for older adults Reply letter to Hollingsworth et al.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Hum Vaccin  Immunother 2013; 9:1382-4;  PMID:23732892 ;  http://dx.doi.org/10.4161/hv.24692 3.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
CMAJ 2009; 180:48- 58; PMID:19124790 ; http://dx.doi.org/10.1503/ cmaj.080734 4.,OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Vaccine 2004; 22:927-46; PMID :15161070 ;  http://dx.doi.org/10.1016/j.vaccine.2003.09.027 6.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Expert Rev Vaccines  2011; 10:1143-67;  PMID:21810065 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Clin Infect Dis 2009; 49:1318-25;  PMID:19814624 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Clin Infect Dis 2011; 52:633-40; PMID:21292668 ;  http://dx.doi.org/10.1093/cid/ciq207 9.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Vaccine  2011; 29:6149-54;  PMID:21763386 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
J Infect Dis  2010; 201:32-41;  PMID:19947881 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Clin Microbiol Infect  2009; 15:1013-9;  PMID:19673968 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Clin Infect Dis 2009; 49:205-12; PMID:19508165 ;  http://dx.doi.org/10.1086/599827 13.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Lancet Infect Dis  2011; 11:760-8;  PMID:21621466 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
MBio 2011; 2:e00309- 10; PMID:21264063 ; http://dx.doi.org/10.1128/ mBio.00309-10 15.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Vaccine 2012; 30:5437- 44; PMID:22728289 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Am J Prev Med 2013; 44:373- 81; PMID:23498103 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
JAMA 2012;  307:804-12;  PMID:22357831 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Hum Vaccin  2011; 7:919-28;  PMID:21860256 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Eur J Clin Microbiol  Infect Dis 2007; 26:531-40; PMID:17570001 ;  http://dx.doi.org/10.1007/s10096-007-0327-z 22.,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
Clin Infect Dis 2012; 55:265-7;  PMID:22495544 ; http://dx.doi.org/10.1093/cid/ cis364,Non-OADS,/arxiv_data1/oa_pdf/2c/18/hvi-10-47.PMC4181016.pdf
"*Correspondence to: Rosalind Hollingsworth; Email: Ros.Hollingsworth@pfizer.com Submitted: 08/01/2013; Revised: 08/19/2013; Accepted: 08/31/2013http://dx.doi.org/10.4161/hv.26330Response to: Fedson DS, Guppy MJ.",Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Hum Vaccin Immunother 2013; 9: 1382-4; PMID:23732892; http://dx.doi.org/10.4161/hv.24692Pneumococcal vaccination of older adults Conjugate or polysaccharide?,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
CMAJ 2009; 180:48- 58; PMID:19124790 ; http://dx.doi.org/10.1503/ cmaj.080734 3.,OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Pediatr Infect Dis J 2006; 25:779-81;  PMID:16940833 ; http://dx.doi.org/10.1097/01.,OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Lancet 2005; 365:1139-46;  PMID :15794968 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Hum Vaccin Immunother 2013; 9: (Forthcoming);  PMID:23732892 ; http://dx.doi.org/10.4161/ hv.246928.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Vaccine 2013; 31:3577-84; PMID:23688526 ;  http://dx.doi.org/10.1016/j.vaccine.2013.04.085 9.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Vaccine 2013; 31:3585-93; PMID:23688527 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Vaccine 2013; 31:3594-602; PMID:23688525 ;  http://dx.doi.org/10.1016/j.vaccine.2013.04.084 11.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Lancet 2007; 369:1179- 86; PMID:17416262 ; http://dx.doi.org/10.1016/ S0140-6736(07)60564-9 12.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Vaccine 2008; 26:4947- 54; PMID:18662735 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
MBio 2011; 2:e00309- 10; PMID:21264063 ; http://dx.doi.org/10.1128/ mBio.00309-10 14.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Clin Vaccine  Immunol 2012; 19:1131-41; PMID :22675155 ;  http://dx.doi.org/10.1128/CVI.00064-12 16.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Am J Prev Med 2013; 44:373- 81; PMID:23498103 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
Vaccine 2012; 30:5437- 44; PMID:22728289 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/87/9e/hvi-10-45.PMC4181019.pdf
"*Correspondence to: Elisabetta Franco; Email: franco@med.uniroma2.it Submitted: 07/04/2013; Revised: 08/08/2013; Accepted: 08/26/2013http://dx.doi.org/10.4161/hv.26269Combined hexavalent diphtheria-tetanus-acellular  pertussis-hepatitis B-inactivated poliovirus- Haemophilus influenzae  type b vaccine—   Infanrix™ hexa Twelve years of experience in Italy vincenzo Baldo1, Paolo Bonanni2, Marcela Castro3, Giovanni Gabutti4, elisabetta Franco5,*, Federico Marchetti6, Rosa Prato7,  and Francesco v itale8 1Department Molecular Medicine; Laboratory of Public Health; University of Padua; Padua, i taly; 2Department of Health Sciences; University of Florence; Florence, i taly;  3GlaxoSmithKline v accines; w avre, Belgium; 4O.U.",Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
"Adapted from publically available data reports of i stituto  Superiore di Sanità-Roma, accessed at http://www.simi.iss.it/files/Report_MB i.pdf and http://www.simi.iss.it/files/Report_meningiti_1994-2006.pdf  April 2013).",OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatr Infect Dis J 2007; 26:496-500;  PMID:17529866 ; http://dx.doi.org/10.1097/ INF.0b013e31805d7f17 2.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatr Infect Dis J 2009; 28:98-101;  PMID:19148039 ; http://dx.doi.org/10.1097/ INF.0b013e318187d047 3.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatr Infect Dis J 2006;  25:507-12;  PMID:16732148 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
2011 Sep 14 [cited  2013 Feb 18]; Available from: http://www.ema.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Expert Rev Vaccines 2007; 6:47-56; PMID:17280478 ;  http://dx.doi.org/10.1586/14760584.6.1.47 7.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Infect Immun 2000; 68:1934-41; PMID:10722585 ;  http://dx.doi.org/10.1128/IAI.68.4.1934-1941.2000 8.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Expert Rev Vaccines  2009; 8:663-78;  PMID:19485747 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatr Infect Dis J 1998; 17:1026-33; PMID:9849987 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Vaccine 1999; 18:884-91; PMID:10580202 ;  http://dx.doi.org/10.1016/S0264-410X(99)00341-2 11.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Available from:  http://www.salute.gov.it/imgs/C_17_pagineA - ree_811_listaFile_itemName_11_file.pdf 13.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Eur J Pediatr 2002; 161:581-7; PMID:12424582 ;  http://dx.doi.org/10.1007/s00431-002-1079-5 14.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Vaccine 2012; 30:2710- 4; PMID:22349525 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Scand J Infect Dis  2004; 36:585-92;  PMID:15370670 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Hum Vaccin 2009; 5:18-25; PMID:18690013 ;  http://dx.doi.org/10.4161/hv.5.1.6369 18.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Clin Vaccine Immunol 2010; 17:1017-26;  PMID:20427630 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Vaccine 2009; 27:3459-62; PMID:19200823 ;  http://dx.doi.org/10.1016/j.vaccine.2009.01.052,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
J Biol Stand 1983; 11:137- 44; PMID:6345548 ; http://dx.doi.org/10.1016/ S0092-1157(83)80038-9 22.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Eur J Clin Microbiol 1987; 6:18-21;  PMID:2883004 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
J Immunol Methods 1987; 103:189-94;  PMID:3668258 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
J Pediatr 1996; 129:695-701; PMID:8917236 ; http://dx.doi.org/10.1016/ S0022-3476(96)70152-X 26.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
JAMA 1996; 275:37- 41; PMID:8531284 ; http://dx.doi.org/10.1001/ jama.1996.03530250041024 27.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
N Engl J Med 1996; 334:341- 8; PMID:8538704 ; http://dx.doi.org/10.1056/ NEJM199602083340601 28.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatrics 2001; 108:E81; PMID:11694665 ;  http://dx.doi.org/10.1542/peds.108.5.e81 29.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Expert Rev Vaccines 2009; 8:1303- 7; PMID:19803750 ; http://dx.doi.org/10.1586/ erv.09.88 30.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Vaccine 2012;  30:3239-47;  PMID:22094282 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Eur J Pediatr 2012; 171:1651- 5; PMID:22790868 ; http://dx.doi.org/10.1007/ s00431-012-1791-8 32.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Vaccine 2007; 25:2634-42;   PMID:17280745 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatr  Infect Dis J 2012; 31:1304-7; PMID:22863911 ;  http://dx.doi.org/10.1097/INF.0b013e31826b7110 36.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
JAMA 2012; 308:2126-32;  PMID:23188029 ;  http://dx.doi.org/10.1001/jama.2012.14939 37.,OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
N Engl J Med  2012; 367:1012-9;  PMID:22970945 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Pediatrics 2013; 131:e1047- 52; PMID:23478868 ; http://dx.doi.org/10.1542/ peds.2012-1928 39.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Available from: http://www.ncirs.edu.au/news/past-news- events/Day%201/HQuinn-Australia-PertussisWS-25_26Aug11.pdf 40.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
Vaccine 2010; 29:45-50;  PMID:20974302 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b4/hvi-10-129.PMC4181021.pdf
